@NP	Schwann Cell Bridges and Olfactory-Ensheathing Glia Grafts	11
@NP	Schwann Cell Bridges	11
@NP	Olfactory-Ensheathing Glia Grafts	36
@NP	Chondroitinase	75
@NP	Locomotor Recovery	99
@NP	Complete Transection of the Spinal Cord Karim Fouad ,1 Lisa Schnell ,2 Mary B.	124
@NP	Complete Transection	124
@NP	the Spinal Cord Karim Fouad ,1 Lisa Schnell ,2 Mary B.	148
@NP	Bunge ,3,4,5 Martin E.	201
@NP	Bunge ,3,4,5	201
@NP	Martin E.	213
@NP	Schwab ,2 Thomas Liebscher ,2 and Damien D.	223
@NP	Schwab ,2 Thomas Liebscher	223
@NP	,2 and Damien D.	248
@NP	,2	248
@NP	Damien D.	255
@NP	Pearse3 ,5 1University	265
@NP	,5	272
@NP	Alberta , Faculty	290
@NP	Rehabilitation Medicine	310
@NP	Edmonton	335
@NP	Canada T6G 2G4	345
@NP	2Brain Research Institute	361
@NP	University of Zurich	388
@NP	University	388
@NP	Zurich	402
@NP	Department	414
@NP	Biology , Swiss Federal Institute	428
@NP	Technology , 8006 Zurich , Switzerland , and 3The Miami Project	464
@NP	Technology	464
@NP	8006 Zurich , Switzerland	476
@NP	3The Miami Project	506
@NP	Paralysis	533
@NP	4Departments of Cell Biology and Anatomy	544
@NP	4Departments	544
@NP	Cell Biology and Anatomy	560
@NP	5Neurological Surgery	589
@NP	University	612
@NP	Miami School of Medicine , Miami , Florida 33101 Numerous obstacles	626
@NP	Miami School	626
@NP	Medicine , Miami , Florida 33101 Numerous obstacles	642
@NP	Medicine , Miami , Florida 33101	642
@NP	Numerous obstacles	674
@NP	successful regeneration of injured axons	696
@NP	successful regeneration	696
@NP	injured axons	723
@NP	the adult mammalian spinal cord	740
@NP	a treatment strategy	793
@NP	axonal regeneration and significant functional recovery	823
@NP	axonal regeneration	823
@NP	significant functional recovery	847
@NP	spinal cord injury	885
@NP	these obstacles	920
@NP	The current study	937
@NP	multiple impediments	976
@NP	regeneration	1000
@NP	a combinatory strategy	1022
@NP	complete spinal cord transection in adult rats	1051
@NP	complete spinal cord transection	1051
@NP	adult rats	1087
@NP	reduce	1106
@NP	inhibitory cues	1113
@NP	the glial scar -LRB- chondroitinase ABC -RRB-	1132
@NP	the glial scar	1132
@NP	chondroitinase ABC	1148
@NP	a growth-supportive substrate	1184
@NP	axonal regeneration	1218
@NP	Schwann cells -LRB- SCs -RRB-	1239
@NP	Schwann cells	1239
@NP	SCs	1254
@NP	and	1261
@NP	regenerated axons	1279
@NP	the bridge to re-enter the spinal cord -LRB- olfactory ensheathing glia -RRB-	1305
@NP	the spinal cord -LRB- olfactory ensheathing glia -RRB-	1328
@NP	the spinal cord	1328
@NP	olfactory ensheathing glia	1345
@NP	The combination	1374
@NP	SC bridge , olfactory ensheathing glia , and chondroitinase ABC	1393
@NP	SC bridge	1393
@NP	olfactory ensheathing glia	1404
@NP	chondroitinase ABC	1436
@NP	significant benefit	1464
@NP	grafts only or the untreated group	1498
@NP	grafts only	1498
@NP	grafts	1498
@NP	the untreated group	1513
@NP	Significant improvements	1534
@NP	the Basso , Beattie , and Bresnahan score	1576
@NP	the Basso	1576
@NP	Beattie	1587
@NP	Bresnahan score	1600
@NP	forelimb/hindlimb coupling	1623
@NP	This recovery	1651
@NP	increased numbers of both myelinated axons in the SC bridge	1684
@NP	increased numbers	1684
@NP	both myelinated axons in the SC bridge	1705
@NP	both myelinated axons	1705
@NP	the SC bridge	1730
@NP	serotonergic fibers that grew through the bridge and into the caudal spinal cord	1748
@NP	serotonergic fibers	1748
@NP	the bridge	1786
@NP	the caudal spinal cord	1806
@NP	prominent descending tracts such as the corticospinal and reticulospinal tracts	1839
@NP	prominent descending tracts	1839
@NP	the corticospinal and reticulospinal tracts	1875
@NP	the bridge	1959
@NP	it	1971
@NP	other populations of regenerated fibers	1988
@NP	other populations	1988
@NP	regenerated fibers	2009
@NP	the driving force for the observed recovery	2033
@NP	the driving force	2033
@NP	the observed recovery	2055
@NP	there	2078
@NP	a significant correlation between numbers of myelinated fibers	2088
@NP	a significant correlation	2088
@NP	numbers of myelinated fibers	2122
@NP	numbers	2122
@NP	myelinated fibers	2133
@NP	the bridge	2154
@NP	coupling of forelimb and hindlimb as well as open-field locomotion	2178
@NP	coupling of forelimb and hindlimb	2178
@NP	coupling	2178
@NP	forelimb and hindlimb	2190
@NP	open-field locomotion	2223
@NP	Our study	2246
@NP	proven experimental treatments	2266
@NP	a well-established animal model	2309
@NP	needed direction	2357
@NP	the development of future combinatory treatment regimens	2378
@NP	the development	2378
@NP	future combinatory treatment regimens	2397
@NP	Introduction Spinal cord injury -LRB- SCI -RRB- in adult mammals	2438
@NP	Introduction Spinal cord injury	2438
@NP	Introduction	2438
@NP	Spinal cord injury	2451
@NP	SCI	2471
@NP	adult mammals	2479
@NP	complex pathophysiological processes	2503
@NP	extensive cell death , incomplete self-repair , and limited axonal regeneration	2557
@NP	extensive cell death	2557
@NP	incomplete self-repair	2579
@NP	limited axonal regeneration	2607
@NP	review	2640
@NP	Schwab and Bartholdi , 1996	2652
@NP	Schwab and Bartholdi	2652
@NP	1996	2674
@NP	These processes	2681
@NP	a combination of strategies	2710
@NP	a combination	2710
@NP	strategies	2727
@NP	ongoing tissue damage	2765
@NP	regrowth and reconnection of axons	2799
@NP	regrowth and reconnection	2799
@NP	axons	2828
@NP	treatments targeting these processes	4062
@NP	treatments	4062
@NP	these processes	4083
@NP	regeneration and functional recovery	4152
@NP	SCI	4195
@NP	the number of regenerating axons	4200
@NP	the number	4200
@NP	regenerating axons	4214
@NP	small and functional recovery modest	4246
@NP	small and functional recovery	4246
@NP	the need to overcome multiple factors that limit axon growth	4297
@NP	multiple factors that limit axon growth	4318
@NP	multiple factors	4318
@NP	axon growth	4346
@NP	it	4370
@NP	a combination of strategies	4393
@NP	a combination	4393
@NP	strategies	4410
@NP	about increased axonal growth and functional recovery	4431
@NP	about increased axonal growth	4431
@NP	functional recovery	4465
@NP	the optimal combination strategy for SCI repair	4503
@NP	the optimal combination strategy	4503
@NP	SCI repair	4540
@NP	a number of studies	4552
@NP	a number	4552
@NP	studies	4564
@NP	the additive potential of two or more therapeutic approaches	4590
@NP	the additive potential	4590
@NP	two or more therapeutic approaches	4616
@NP	Such strategies	4652
@NP	cell	4676
@NP	approaches	4695
@NP	neuroprotective agents -LRB- Pearse et al. , 2004b -RRB-	4716
@NP	neuroprotective agents	4716
@NP	Pearse	4740
@NP	et al. , 2004b	4747
@NP	et al.	4747
@NP	2004b	4755
@NP	exogenous or cellular overexpressed growth factors	4763
@NP	Xu	4815
@NP	et al. , 1995a	4818
@NP	et al.	4818
@NP	1995a	4826
@NP	Bregman et al. , 1997	4833
@NP	Bregman	4833
@NP	et al. , 1997	4841
@NP	et al.	4841
@NP	1997	4849
@NP	Menei et al. , 1998	4855
@NP	Menei	4855
@NP	et al. , 1998	4861
@NP	et al.	4861
@NP	1998	4869
@NP	Coumans et al. , 2001	4875
@NP	Coumans	4875
@NP	et al. , 2001	4883
@NP	et al.	4883
@NP	2001	4891
@NP	elevation ofcAMP	4898
@NP	Lu et al. , 2004 ; Nikulina et al. , 2004 ; Pearse et al. , 2004a	4915
@NP	Lu	4915
@NP	et al. , 2004 ; Nikulina et al. , 2004 ; Pearse et al. , 2004a	4918
@NP	et al. , 2004	4918
@NP	et al.	4918
@NP	2004	4926
@NP	Nikulina et al. , 2004	4932
@NP	Nikulina	4932
@NP	et al. , 2004	4941
@NP	et al.	4941
@NP	2004	4949
@NP	Pearse et al. , 2004a	4955
@NP	Pearse	4955
@NP	et al. , 2004a	4962
@NP	et al.	4962
@NP	2004a	4970
@NP	scar-reducing enzymes -LRB- Chau et al. , 2004 -RRB-	4981
@NP	scar-reducing enzymes	4981
@NP	Chau	5004
@NP	et al. , 2004	5009
@NP	et al.	5009
@NP	2004	5017
@NP	Combinatory pharmacological therapies	5024
@NP	Guth et al. , 1994 ; Mu et al. , 2000	5085
@NP	Guth	5085
@NP	et al. , 1994 ; Mu et al. , 2000	5090
@NP	et al. , 1994	5090
@NP	et al.	5090
@NP	1994	5098
@NP	Mu et al. , 2000	5104
@NP	Mu	5104
@NP	et al. , 2000	5107
@NP	et al.	5107
@NP	2000	5115
@NP	Schwann cell -LRB- SC -RRB- implants	5137
@NP	the addition	5178
@NP	methylprednisolone -LRB- Chen et al. , 1996 -RRB-	5194
@NP	methylprednisolone	5194
@NP	Chen	5214
@NP	et al. , 1996	5219
@NP	et al.	5219
@NP	1996	5227
@NP	neurotrophins	5234
@NP	Xu	5249
@NP	et al. , 1995a	5252
@NP	et al.	5252
@NP	1995a	5260
@NP	Menei et al. , 1998	5267
@NP	Menei	5267
@NP	et al. , 1998	5273
@NP	et al.	5273
@NP	1998	5281
@NP	Weidner et al. , 1999	5287
@NP	Weidner	5287
@NP	et al. , 1999	5295
@NP	et al.	5295
@NP	1999	5303
@NP	Bamber et al. , 2001	5309
@NP	Bamber	5309
@NP	et al. , 2001	5316
@NP	et al.	5316
@NP	2001	5324
@NP	olfactory ensheathing glia -LRB- OEG -RRB-	5331
@NP	olfactory ensheathing glia	5331
@NP	OEG	5359
@NP	Ramo ' n-Cueto et al. , 1998	5365
@NP	Ramo ' n-Cueto et al.	5365
@NP	Ramo ' n-Cueto	5365
@NP	Ramo '	5365
@NP	1998	5387
@NP	elevated cAMP -LRB- Pearse et al. , 2004a -RRB-	5397
@NP	elevated cAMP	5397
@NP	Pearse	5412
@NP	et al. , 2004a	5419
@NP	et al.	5419
@NP	2004a	5427
@NP	axonal regeneration	5457
@NP	The current study	5478
@NP	a combination of interventions	5504
@NP	a combination	5504
@NP	interventions	5521
@NP	inhibitory cues of the scar tissue -LRB- chondroitinase ABC -RRB-	5547
@NP	inhibitory cues	5547
@NP	the scar tissue -LRB- chondroitinase ABC -RRB-	5566
@NP	the scar tissue	5566
@NP	chondroitinase ABC	5583
@NP	chondroitinase	5583
@NP	ABC	5598
@NP	a growth-supportive substrate for axonal regeneration -LRB- SC bridge -RRB-	5614
@NP	a growth-supportive substrate	5614
@NP	axonal regeneration -LRB- SC bridge -RRB-	5648
@NP	axonal regeneration	5648
@NP	SC bridge	5669
@NP	regenerated axons	5693
@NP	the bridge -LRB- OEG -RRB- in adult rats	5720
@NP	the bridge -LRB- OEG -RRB-	5720
@NP	the bridge	5720
@NP	OEG	5732
@NP	adult rats	5740
@NP	complete spinal cord transection	5756
@NP	Materials and Methods Cell culture Schwann cells .	5791
@NP	Materials and Methods	5791
@NP	Materials	5791
@NP	Methods	5805
@NP	Cell culture Schwann cells	5813
@NP	Cell culture	5813
@NP	Schwann cells	5826
@NP	SCs	5841
@NP	sciatic nerves	5864
@NP	adult female Fischer rats -LRB- Harlan , Indianapolis , IN -RRB-	5882
@NP	adult female Fischer rats	5882
@NP	Morrissey	5960
@NP	et al. , 1991	5970
@NP	et al.	5970
@NP	1991	5978
@NP	Nerves	5985
@NP	small pieces	6006
@NP	culture dishes in DMEM/10 % heat-inactivated fetal bovine serum -LRB- FBS -RRB-	6033
@NP	culture dishes	6033
@NP	DMEM/10 % heat-inactivated fetal bovine serum -LRB- FBS -RRB-	6051
@NP	DMEM/10 % heat-inactivated fetal bovine serum	6051
@NP	DMEM/10 %	6051
@NP	FBS	6096
@NP	mitogens	6109
@NP	2 weeks	6125
@NP	the pieces	6134
@NP	new dishes	6165
@NP	they	6182
@NP	DMEM/10 %	6239
@NP	FBS supplemented with three	6248
@NP	FBS	6248
@NP	three	6270
@NP	two , mitogens	6289
@NP	two	6289
@NP	mitogens	6294
@NP	bovine pituitary extract	6304
@NP	2 mg/ml ; Invitrogen Corporation , Carlsbad , CA	6330
@NP	2 mg/ml	6330
@NP	Invitrogen Corporation , Carlsbad , CA	6339
@NP	forskolin -LRB- 0.8 µg/ml -RRB-	6378
@NP	forskolin	6378
@NP	0.8 µg/ml	6389
@NP	heregulin -LRB- 2.5 nM ; Genentech , San Francisco , CA -RRB-	6405
@NP	heregulin	6405
@NP	2.5 nM ; Genentech	6416
@NP	2.5 nM	6416
@NP	Genentech	6424
@NP	San Francisco , CA	6435
@NP	San Francisco	6435
@NP	CA	6450
@NP	Meijs	6479
@NP	et al. , 2004	6485
@NP	et al.	6485
@NP	2004	6493
@NP	The purity of the SCs assessed by using the S100 and Hoechst stains	6500
@NP	The purity	6500
@NP	the SCs assessed by using the S100 and Hoechst stains	6514
@NP	the SCs	6514
@NP	the S100 and Hoechst stains	6540
@NP	95 -- 98 %	6572
@NP	95	6572
@NP	98 %	6575
@NP	Olfactory ensheathing glia	6580
@NP	cultures of OEG	6624
@NP	cultures	6624
@NP	OEG	6636
@NP	the nerve fiber	6659
@NP	layer	6675
@NP	the olfactory bulb	6684
@NP	adult female Fischer rats	6706
@NP	Harlan	6733
@NP	a procedure	6747
@NP	one described previously -LRB- Ramo ' n-Cueto et al. , 1998 -RRB-	6773
@NP	one	6773
@NP	Ramo ' n-Cueto et al. , 1998	6799
@NP	Ramo ' n-Cueto et al.	6799
@NP	Ramo ' n-Cueto	6799
@NP	Ramo '	6799
@NP	1998	6821
@NP	The pia	6828
@NP	care	6852
@NP	the inclusion of non-nerve fiber layer bulb tissue	6879
@NP	the inclusion	6879
@NP	non-nerve fiber layer bulb tissue	6896
@NP	OEG	6931
@NP	the method of Ramo ' n-Cueto et al. -LRB- 1998 -RRB-	6964
@NP	the method	6964
@NP	Ramo ' n-Cueto et al. -LRB- 1998 -RRB-	6978
@NP	Ramo ' n-Cueto	6978
@NP	Ramo '	6978
@NP	et al. -LRB- 1998 -RRB-	6992
@NP	et al.	6992
@NP	1998	7000
@NP	5 d	7024
@NP	forskolin -LRB- 0.8 µg/ml -RRB- and pituitary extract -LRB- 2 mg/ml -RRB-	7031
@NP	forskolin	7031
@NP	0.8 µg/ml	7042
@NP	pituitary extract	7057
@NP	2 mg/ml	7076
@NP	DMEM/F -12	7088
@NP	10 % FBS before purification	7098
@NP	10 % FBS	7098
@NP	purification	7113
@NP	p75 immuno-panning as described previously -LRB- Takami et al. , 2002 -RRB-	7129
@NP	p75 immuno-panning	7129
@NP	Takami	7173
@NP	et al. , 2002	7180
@NP	et al.	7180
@NP	2002	7188
@NP	The OEG	7195
@NP	2 passages -LRB- at ≈ 18 d after extraction from the olfactory bulb -RRB-	7219
@NP	2 passages	7219
@NP	≈ 18 d after extraction from the olfactory bulb	7234
@NP	≈ 18 d	7234
@NP	extraction from the olfactory bulb	7246
@NP	extraction	7246
@NP	the olfactory bulb	7262
@NP	A second period in mitogens	7283
@NP	A second period	7283
@NP	mitogens	7302
@NP	confluency for transplantation	7334
@NP	confluency	7334
@NP	transplantation	7349
@NP	the purity	7375
@NP	SCs	7401
@NP	that p75 , rather than S100 ,	7412
@NP	that p75	7412
@NP	S100	7434
@NP	Hoechst nuclear staining	7454
@NP	Purity	7480
@NP	between 94 and 98 %	7503
@NP	Preparation of the cells for grafting .	7523
@NP	Preparation	7523
@NP	the cells for grafting	7538
@NP	the cells	7538
@NP	grafting	7552
@NP	SCs or OEG	7571
@NP	DMEM/F -12 medium	7600
@NP	transplantation	7625
@NP	OEG	7642
@NP	them	7673
@NP	the dishes	7683
@NP	the cells	7699
@NP	a hemocytometer	7728
@NP	SCs	7745
@NP	a 60:40 -LRB- v/v -RRB- solution	7769
@NP	DMEM/F -12 : Matrigel -LRB- BD Biosciences , San Jose , CA -RRB-	7795
@NP	DMEM/F -12	7795
@NP	Matrigel	7805
@NP	BD Biosciences	7815
@NP	San Jose	7831
@NP	CA	7841
@NP	Each animal	7874
@NP	a total of 5 x 106 SCs for transplantation	7895
@NP	a total of 5	7895
@NP	a total	7895
@NP	5	7906
@NP	106 SCs for transplantation	7910
@NP	106 SCs	7910
@NP	transplantation	7922
@NP	OEG	7939
@NP	aliquots of 4 µl of DMEM/F -12 medium	7963
@NP	aliquots	7963
@NP	4 µl of DMEM/F -12 medium	7975
@NP	4 µl	7975
@NP	DMEM/F -12 medium	7983
@NP	4 x 105 cells immediately	8011
@NP	4 x	8011
@NP	105 cells	8015
@NP	spinal cord injection	8044
@NP	Surgical procedures The experiments	8067
@NP	Surgical procedures	8067
@NP	The experiments	8087
@NP	adult female Fischer rats	8124
@NP	165	8151
@NP	180 g ; Charles River Laboratories , Wilmington , MA	8156
@NP	180 g	8156
@NP	Charles River Laboratories , Wilmington , MA	8163
@NP	Charles River Laboratories	8163
@NP	Wilmington , MA	8191
@NP	All rats	8208
@NP	a 12 h light/dark cycle	8230
@NP	water and food ad libitum.Acomplete injury model	8267
@NP	water	8267
@NP	food ad libitum.Acomplete injury model	8277
@NP	regeneration of axons	8329
@NP	regeneration	8329
@NP	axons	8345
@NP	The experiment	8385
@NP	the animal welfare committee	8416
@NP	the University of Alberta	8448
@NP	the University	8448
@NP	Alberta	8466
@NP	arrival	8481
@NP	the rats	8490
@NP	2 weeks	8516
@NP	Ensure	8545
@NP	complete meal replacement	8553
@NP	Ross products division ; Abbott Laboratories	8580
@NP	Ross products division	8580
@NP	Abbott Laboratories	8604
@NP	Irving , TX	8625
@NP	a syringe	8642
@NP	The treatments	9138
@NP	Fig. 1	9172
@NP	The IgG	9180
@NP	the experiment	9210
@NP	a control for an additional treatment group , which is not reported here	9228
@NP	a control	9228
@NP	an additional treatment group , which is not reported here	9242
@NP	an additional treatment group	9242
@NP	Spinal cord transection and Schwann cell grafting Animals	9301
@NP	Spinal cord transection and Schwann cell	9301
@NP	Animals	9351
@NP	a subcutaneous injection	9382
@NP	Hypnorm	9410
@NP	120 µl per 200 g body weight ; Janssen Pharmaceutics , Beerse , Belgium	9419
@NP	120 µl	9419
@NP	200 g body weight ; Janssen Pharmaceutics , Beerse , Belgium	9430
@NP	200 g body weight	9430
@NP	Janssen Pharmaceutics , Beerse , Belgium	9449
@NP	Janssen Pharmaceutics	9449
@NP	Beerse , Belgium	9472
@NP	Midazolam	9493
@NP	0.75 mg in 150 µl/200 g body weight	9504
@NP	0.75 mg in 150 µl/200	9504
@NP	0.75 mg	9504
@NP	150 µl/200	9515
@NP	g body weight	9526
@NP	750 µl total volume	9541
@NP	H2O ; Sabex , Boucherville , Quebec , Canada	9574
@NP	H2O	9574
@NP	Sabex , Boucherville , Quebec , Canada	9579
@NP	Eye lubricant	9617
@NP	Tears Naturale ; Alcon , Mississauga , Ontario , Canada	9632
@NP	Tears Naturale	9632
@NP	Alcon , Mississauga , Ontario , Canada	9648
@NP	the eyes	9708
@NP	dehydration	9722
@NP	a laminectomy at the T 7.5 -- 9 vertebral level	9741
@NP	a laminectomy at the T 7.5	9741
@NP	a laminectomy	9741
@NP	the T 7.5	9758
@NP	9 vertebral level	9768
@NP	the meningeal membranes	9787
@NP	the dura mater	9835
@NP	the spinal cord	9851
@NP	a 4 mmregion of spinal cord encompassing T8	9898
@NP	a 4 mmregion	9898
@NP	spinal cord encompassing T8	9914
@NP	spinal cord	9914
@NP	T8	9939
@NP	The rostral and caudal stumps	9955
@NP	The rostral	9955
@NP	caudal stumps	9971
@NP	removal of the spinal cord segment	10003
@NP	removal	10003
@NP	the spinal cord segment	10014
@NP	complete discontinuity	10048
@NP	All spinal roots visible in the injury gap	10072
@NP	All spinal roots	10072
@NP	the injury gap	10100
@NP	bleeding	10133
@NP	Gelfoam -LRB- Upjohn , Kalamazoo , MI -RRB-	10160
@NP	Gelfoam	10160
@NP	Upjohn	10169
@NP	Kalamazoo	10177
@NP	MI	10188
@NP	≈ 2 x 105 OEG	10205
@NP	≈ 2	10205
@NP	105 OEG	10210
@NP	a glass pipette	10234
@NP	a tip diameter of 150	10255
@NP	a tip diameter	10255
@NP	150	10273
@NP	200 µm	10277
@NP	a 5 µl	10297
@NP	Hamilton syringe -LRB- Hamilton , Reno , NV -RRB- attached to a micromanipulator	10304
@NP	Hamilton syringe	10304
@NP	Hamilton	10322
@NP	Reno	10332
@NP	NV	10338
@NP	a micromanipulator	10354
@NP	The cells	10374
@NP	two injection sites at the rostral	10404
@NP	two injection sites	10404
@NP	the rostral	10427
@NP	the caudal stump , ≈ 2 mm from the lesion ,	10450
@NP	the caudal stump	10450
@NP	≈ 2 mm from the lesion	10468
@NP	≈ 2 mm	10468
@NP	the lesion	10479
@NP	300 µm lateral to the midline	10494
@NP	300 µm lateral	10494
@NP	the midline	10512
@NP	a depth of 800 µm	10532
@NP	a depth	10532
@NP	800 µm	10543
@NP	A volume of 1 µl containing ≈ 105 OEG in DMEM/F -12	10551
@NP	A volume	10551
@NP	1 µl containing ≈ 105 OEG in DMEM/F -12	10563
@NP	1 µl	10563
@NP	≈ 105 OEG	10579
@NP	DMEM/F -12	10591
@NP	each site	10618
@NP	the rostral cord stump	10635
@NP	2 mm	10671
@NP	6 mm-long hollow , semipermeable 60:40 polyacrylonitrile/polyvinylchloride	10683
@NP	channel -LRB- 2.6 mm inner diameter , 3.0 mm outer diameter ; provided by T.	10776
@NP	channel -LRB- 2.6 mm inner diameter , 3.0 mm outer diameter ;	10776
@NP	channel	10776
@NP	2.6 mm inner diameter , 3.0 mm outer diameter	10785
@NP	2.6 mm	10785
@NP	inner diameter , 3.0 mm outer diameter	10792
@NP	inner diameter	10792
@NP	3.0 mm outer diameter	10808
@NP	3.0 mm	10808
@NP	outer diameter	10815
@NP	T.	10843
@NP	Hazlett	10846
@NP	CytoTherapeutics , Providence , RI -RRB- , previously cleaned	10855
@NP	CytoTherapeutics , Providence , RI -RRB- ,	10855
@NP	CytoTherapeutics	10855
@NP	Providence	10873
@NP	RI	10885
@NP	sterilized -LRB- Aebischer et al. , 1988 -RRB-	10913
@NP	sterilized	10913
@NP	Aebischer	10925
@NP	et al. , 1988	10935
@NP	et al.	10935
@NP	1988	10943
@NP	The channel	10950
@NP	1 mm	10982
@NP	the insertion of the caudal stump	10997
@NP	the insertion	10997
@NP	the caudal stump	11014
@NP	the channel	11039
@NP	two small windows	11060
@NP	the dorsal surface of the channel	11105
@NP	the dorsal surface	11105
@NP	the channel	11127
@NP	implantation	11146
@NP	30 µl	11167
@NP	SCs	11176
@NP	a 60:40 -LRB- v/v -RRB- solution of DMEM/F -12	11193
@NP	a 60:40 -LRB- v/v -RRB- solution	11193
@NP	DMEM/F -12	11219
@NP	Matrigel	11229
@NP	the channel	11253
@NP	The windows	11266
@NP	Matrigel	11311
@NP	surgery	11325
@NP	5 min	11348
@NP	semisolidification of the Matrigel-SC cable	11363
@NP	semisolidification	11363
@NP	the Matrigel-SC cable	11385
@NP	37 °C	11410
@NP	addition to the drug delivery using pumps -LRB- see below -RRB-	11419
@NP	addition	11419
@NP	the drug delivery using pumps -LRB- see below -RRB-	11431
@NP	the drug delivery	11431
@NP	pumps	11455
@NP	the lesion	11498
@NP	the wound	11510
@NP	chondroitinase or vehicle	11536
@NP	The surgeon	11563
@NP	both kinds of treatments	11591
@NP	both kinds	11591
@NP	treatments	11605
@NP	cABC delivery A double catheter	11617
@NP	cABC delivery A	11617
@NP	double catheter	11633
@NP	two fine catheters -LRB- Re - CathCo , Allison Park , PA -RRB-	11676
@NP	two fine catheters	11676
@NP	Re	11696
@NP	CathCo , Allison Park , PA	11700
@NP	CathCo	11700
@NP	Allison Park	11708
@NP	PA	11722
@NP	a connecting tube	11731
@NP	the minipumps -LRB- model 2002 ; Alzet , Cupertino , CA -RRB-	11754
@NP	the minipumps	11754
@NP	model 2002 ; Alzet , Cupertino , CA	11769
@NP	model 2002	11769
@NP	Alzet , Cupertino , CA	11781
@NP	The ends	11804
@NP	deliv	11833
@NP	ery	11840
@NP	the rostral	11847
@NP	caudal spinal cord	11863
@NP	the guidance channel	11890
@NP	the delivery	11926
@NP	the chondroitinase -LRB- cABC ; Seikagaku America , East Falmouth , MA -RRB-	11942
@NP	the chondroitinase	11942
@NP	cABC ; Seikagaku America	11962
@NP	cABC	11962
@NP	Seikagaku America	11968
@NP	East Falmouth , MA	11987
@NP	East Falmouth	11987
@NP	MA	12002
@NP	the sites of scarring at the SC bridge	12009
@NP	the sites	12009
@NP	scarring at the SC bridge	12022
@NP	scarring	12022
@NP	the SC bridge	12034
@NP	host spinal cord interfaces	12049
@NP	The tubing	12078
@NP	sutures	12104
@NP	the caudal musculature	12115
@NP	The connected minipump	12139
@NP	sterile 0.9 % NaCl	12172
@NP	the catheters	12198
@NP	the intervals between cABC injections	12225
@NP	the intervals	12225
@NP	cABC injections	12247
@NP	2µl of 10µg/ml cABC	12264
@NP	2µl	12264
@NP	10µg/ml cABC	12271
@NP	Injections	12286
@NP	every other day for 4 weeks	12312
@NP	every other day	12312
@NP	4 weeks	12332
@NP	short isoflurane anesthesia	12346
@NP	Pumps	12375
@NP	skin pouches	12398
@NP	the back of the rats	12414
@NP	the back	12414
@NP	the rats	12426
@NP	position	12447
@NP	sutures	12461
@NP	the overlying muscles	12479
@NP	layers	12517
@NP	the skin	12529
@NP	wound clips	12554
@NP	Antibody delivery A fine -LRB- 32 gauge -RRB- intrathecal catheter	12567
@NP	Antibody delivery A fine	12567
@NP	32 gauge	12593
@NP	intrathecal catheter	12603
@NP	ReCathCo	12625
@NP	the lumbar level to its delivery site	12664
@NP	the lumbar level	12664
@NP	its delivery site	12684
@NP	the caudal SC bridge / host spinal cord interface	12705
@NP	the caudal SC bridge	12705
@NP	host spinal cord interface	12727
@NP	host	12727
@NP	spinal cord interface	12732
@NP	The catheter	12755
@NP	the antibody -LRB- model 2002 ; Alzet -RRB-	12777
@NP	the antibody	12777
@NP	model 2002 ; Alzet	12791
@NP	model 2002	12791
@NP	Alzet	12803
@NP	the injury site	12813
@NP	4 weeks	12833
@NP	Pumps	12842
@NP	antibody -LRB- IgG -RRB-	12858
@NP	antibody	12858
@NP	IgG	12868
@NP	a concentration of 3 mg/ml	12876
@NP	a concentration	12876
@NP	3 mg/ml	12895
@NP	PBS	12906
@NP	the delivery rate of the pumps	12915
@NP	the delivery rate	12915
@NP	the pumps	12936
@NP	0.6 µl/h -LRB- ≈ 1.8 µg/h -RRB-	12950
@NP	0.6 µl/h	12950
@NP	≈ 1.8 µg/h	12960
@NP	≈	12960
@NP	1.8 µg/h	12961
@NP	surgery	12978
@NP	the animals	12987
@NP	a thermostatically regulated heating pad	13012
@NP	The analgesic Buprenex	13077
@NP	buprenorphine ; Reckitt and Colman	13101
@NP	buprenorphine	13101
@NP	Reckitt and Colman	13116
@NP	Richmond , VA	13136
@NP	Richmond	13136
@NP	VA	13146
@NP	0.03 mg/kg	13183
@NP	operation and every 8 h	13213
@NP	operation	13213
@NP	every 8 h	13227
@NP	74 h.	13241
@NP	Ringer 's solution -LRB- 4 ml -RRB-	13247
@NP	Ringer 's solution	13247
@NP	Ringer 's	13247
@NP	4 ml	13266
@NP	the first week	13307
@NP	later stages	13329
@NP	animals	13345
@NP	signs of dehydration	13360
@NP	signs	13360
@NP	dehydration	13369
@NP	The antibiotic	13382
@NP	cefazolin -LRB- 5 mg/kg , s.c. ; Novopharm , Toronto , Ontario , Canada -RRB-	13398
@NP	cefazolin	13398
@NP	5 mg/kg , s.c. ; Novopharm , Toronto , Ontario , Canada	13409
@NP	5 mg/kg	13409
@NP	s.c. ; Novopharm , Toronto , Ontario , Canada	13418
@NP	s.c.	13418
@NP	Novopharm , Toronto , Ontario , Canada	13424
@NP	each day	13483
@NP	4 d	13496
@NP	1 d before surgery	13512
@NP	1 d	13512
@NP	surgery	13523
@NP	Bladders	13532
@NP	three times per day	13556
@NP	three times	13556
@NP	day	13572
@NP	the voiding reflex of the bladder was reestablished	13582
@NP	the voiding	13582
@NP	reflex of the bladder	13594
@NP	reflex	13594
@NP	the bladder	13604
@NP	2 weeks after injury	13639
@NP	2 weeks	13639
@NP	injury	13653
@NP	up to 1 ml of Ensure -LRB- chocolate or vanilla -RRB-	13661
@NP	up to 1 ml of Ensure	13661
@NP	1	13667
@NP	ml	13669
@NP	Ensure	13675
@NP	chocolate or vanilla	13683
@NP	chocolate	13683
@NP	vanilla	13696
@NP	each rat	13716
@NP	twice each day	13725
@NP	2 weeks	13747
@NP	pumps	13756
@NP	isoflurane anesthesia	13783
@NP	4 weeks	13813
@NP	pumps and catheters	13822
@NP	chondroitin sulfate digestions	13867
@NP	cABC	13918
@NP	chondroitin sulfate	13932
@NP	the host cord/SC graft interface	13955
@NP	three monoclonal antibodies	13989
@NP	either intact or digested chondroitin sulfate	14032
@NP	immunochemical staining	14092
@NP	alternative spinal cord sections	14119
@NP	2 week cABC-treated -LRB- n = 2 -RRB- or galactosidase-treated grafted animals	14155
@NP	2 week	14155
@NP	n = 2	14176
@NP	n	14176
@NP	= 2	14178
@NP	n	14225
@NP	3	14229
@NP	One antibody , 2B6 -LRB- 1:150 ; Seikagaku America -RRB- ,	14233
@NP	One antibody	14233
@NP	2B6 -LRB- 1:150 ; Seikagaku America -RRB-	14247
@NP	2B6	14247
@NP	1:150 ; Seikagaku America	14252
@NP	1:150	14252
@NP	Seikagaku America	14259
@NP	an epitope created after cABC degradation of chondroitin-4 sulfate	14290
@NP	an epitope	14290
@NP	cABC degradation of chondroitin-4 sulfate	14315
@NP	cABC degradation	14315
@NP	chondroitin-4 sulfate	14335
@NP	the intact form -LRB- Moon et al. , 2001 -RRB-	14379
@NP	the intact form	14379
@NP	Moon	14396
@NP	et al. , 2001	14401
@NP	et al.	14401
@NP	2001	14409
@NP	The other antibodies used	14416
@NP	The other antibodies	14416
@NP	CS-56 -LRB- 1:500 ; Sigma-Aldrich , St.	14447
@NP	CS-56 -LRB- 1:500 ; Sigma-Aldrich ,	14447
@NP	CS-56	14447
@NP	1:500 ; Sigma-Aldrich	14454
@NP	1:500	14454
@NP	Sigma-Aldrich	14461
@NP	Louis , MO -RRB- , which recognizes an epitope	14480
@NP	Louis , MO -RRB-	14480
@NP	Louis	14480
@NP	an epitope	14509
@NP	located on various intact chondroitin sulfate glycosaminoglycan chains	14520
@NP	various intact chondroitin	14531
@NP	1D1	14596
@NP	1:200	14601
@NP	Developmental Studies Hybridoma Bank , University of Iowa , Iowa City , IA	14608
@NP	Developmental Studies Hybridoma Bank , University	14608
@NP	Iowa , Iowa City , IA	14660
@NP	the CSPG core protein of neurocan -LRB- Moon et al. , 2002 -RRB-	14699
@NP	the CSPG core protein	14699
@NP	neurocan -LRB- Moon et al. , 2002 -RRB-	14724
@NP	neurocan	14724
@NP	Moon	14734
@NP	et al. , 2002	14739
@NP	et al.	14739
@NP	2002	14747
@NP	An increase of 2B6	14754
@NP	An increase	14754
@NP	2B6	14769
@NP	a reduction	14777
@NP	the amount of either CS-56 or 1D1 immunoreactivity	14792
@NP	the amount	14792
@NP	either CS-56 or 1D1 immunoreactivity	14806
@NP	CS-56	14813
@NP	1D1 immunoreactivity	14822
@NP	the interface	14846
@NP	cABC efficacy	14875
@NP	changes	14901
@NP	immunoreactivity intensity	14912
@NP	2B6 , CS-56 , and 1D1 at the caudal host cord/SC graft interface	14942
@NP	2B6 , CS-56 , and 1D1	14942
@NP	the caudal host cord/SC graft interface	14965
@NP	40 µm sagittal sections at every 200µm -LRB- 10 -- 12 sections/animal -RRB-	15006
@NP	40 µm sagittal sections	15006
@NP	every 200µm -LRB- 10 -- 12 sections/animal -RRB-	15033
@NP	every 200µm	15033
@NP	10 -- 12 sections/animal	15046
@NP	10	15046
@NP	12 sections/animal	15049
@NP	computer-assisted microscopy and MetaMorph software	15090
@NP	Universal Imaging Corporation , West Chester , PA	15143
@NP	Universal Imaging Corporation	15143
@NP	West Chester	15174
@NP	PA	15188
@NP	each section	15196
@NP	images	15210
@NP	an 800x800 µm area	15230
@NP	both SC and the contiguous host cord region of the caudal interface	15269
@NP	both SC	15269
@NP	the contiguous host cord region of the caudal interface	15281
@NP	the contiguous host cord region	15281
@NP	the caudal interface	15316
@NP	a line drawn through the center of the cord	15356
@NP	a line	15356
@NP	the center of the cord	15377
@NP	the center	15377
@NP	the cord	15391
@NP	Immunoreactivity intensity	15416
@NP	arbitrary units ; higher value indicating greater staining	15444
@NP	arbitrary units	15444
@NP	higher value indicating greater staining	15461
@NP	higher value	15461
@NP	greater staining	15485
@NP	each antibody at the caudal interface	15507
@NP	each antibody	15507
@NP	the caudal interface	15524
@NP	animal	15564
@NP	intensity values	15593
@NP	all sections examined	15617
@NP	all sections	15617
@NP	Testing locomotor recovery Recovery of hindlimb stepping movements	15640
@NP	Testing locomotor recovery Recovery	15640
@NP	hindlimb	15679
@NP	movements	15697
@NP	several locomotor tests	15727
@NP	recovery	15772
@NP	increased excitability of spinal networks	15801
@NP	increased excitability	15801
@NP	spinal networks	15827
@NP	partial reestablishment of descending control	15849
@NP	partial reestablishment	15849
@NP	descending control	15876
@NP	Basso , Beattie , and Bresnahan	15896
@NP	The open-field locomotor score -LRB- Basso et al. , 1995 -RRB-	15933
@NP	The open-field locomotor score	15933
@NP	Basso	15965
@NP	et al. , 1995	15971
@NP	et al.	15971
@NP	1995	15979
@NP	two blinded observers	16003
@NP	testing	16033
@NP	bladders	16042
@NP	spontaneous bladder contraction	16075
@NP	hindlimb activity	16125
@NP	The rats	16144
@NP	a transparent Plexiglas box -LRB- 30 x 90 x 120 cm -RRB-	16168
@NP	a transparent Plexiglas box	16168
@NP	30	16197
@NP	x 90 x 120 cm	16200
@NP	90	16202
@NP	120 cm	16207
@NP	a smooth floor	16220
@NP	4 min	16257
@NP	Hindlimb movements	16264
@NP	contact with experimenters	16301
@NP	contact	16301
@NP	experimenters	16314
@NP	the open-field activity	16353
@NP	the animals	16378
@NP	a digital camera	16421
@NP	a shutter speed of 1/250 s for additional analysis of forelimb/hindlimb coupling	16444
@NP	a shutter speed	16444
@NP	1/250 s for additional analysis of forelimb/hindlimb coupling	16463
@NP	1/250 s	16463
@NP	additional analysis of forelimb/hindlimb coupling	16475
@NP	additional analysis	16475
@NP	forelimb/hindlimb coupling	16498
@NP	Forelimb/hindlimb coupling .	16526
@NP	Forelimb/hindlimb	16526
@NP	coupling	16544
@NP	This analysis	16554
@NP	valuable information	16573
@NP	the Basso , Beattie , and Bresnahan -LRB- BBB -RRB- score	16597
@NP	the Basso	16597
@NP	Beattie	16608
@NP	Bresnahan -LRB- BBB -RRB- score	16621
@NP	both the frequency of hindlimb activity and the coordination with the forelimb	16652
@NP	the frequency of hindlimb activity	16657
@NP	the frequency	16657
@NP	hindlimb activity	16674
@NP	the coordination with the forelimb	16696
@NP	the coordination	16696
@NP	the forelimb	16718
@NP	walking sequences	16738
@NP	account	16771
@NP	hindlimb coupling	16802
@NP	the order of steps made by an ipsilateral forelimb / hindlimb pair was recorded	16821
@NP	the order	16821
@NP	steps made by an ipsilateral forelimb / hindlimb pair was recorded	16834
@NP	steps	16834
@NP	an ipsilateral forelimb / hindlimb pair was recorded	16848
@NP	an ipsilateral forelimb	16848
@NP	hindlimb pair	16873
@NP	Percentage scores of forelimb/hindlimb coupling	16901
@NP	Percentage scores	16901
@NP	forelimb/hindlimb coupling	16922
@NP	the number of correct couplings	16977
@NP	the number	16977
@NP	correct couplings	16991
@NP	a forelimb step	17019
@NP	a hindlimb step , or vice	17051
@NP	a hindlimb step	17051
@NP	vice	17071
@NP	the total number	17086
@NP	couplings	17106
@NP	the sequence -LRB- the number of steps in the sequence minus one -RRB-	17119
@NP	the sequence	17119
@NP	the number of steps in the sequence minus one	17133
@NP	the number	17133
@NP	steps in the sequence minus one	17147
@NP	steps	17147
@NP	the sequence minus one	17156
@NP	this analysis	17185
@NP	five video sequences per animal , with a minimum of six forelimb steps ,	17200
@NP	five video sequences	17200
@NP	animal	17225
@NP	a minimum of six forelimb steps	17238
@NP	a minimum	17238
@NP	six forelimb steps	17251
@NP	Role of sensory feedback on hindlimb movement .	17284
@NP	Role	17284
@NP	sensory feedback	17292
@NP	hindlimb movement	17312
@NP	A major issue	17331
@NP	testing locomotor recovery	17350
@NP	whether hindlimb movements	17391
@NP	volitional drive	17435
@NP	sensory feedback	17458
@NP	the hindlimbs	17480
@NP	the ground	17517
@NP	this question	17544
@NP	we	17559
@NP	open-field locomotion	17569
@NP	different surfaces	17594
@NP	addition to the smooth Plexiglas surface in the open field described above	17617
@NP	addition	17617
@NP	the smooth Plexiglas surface in the open field described above	17629
@NP	the smooth Plexiglas surface	17629
@NP	the open field described above	17661
@NP	the open field	17661
@NP	we	17693
@NP	a slippery surface and a rough surface	17701
@NP	a slippery surface	17701
@NP	a rough surface	17724
@NP	These tests	17741
@NP	the literature	17792
@NP	locomotion	17816
@NP	a slippery surface	17830
@NP	we	17850
@NP	a Plexiglas runway -LRB- 80 x 10 cm , with 10 cm high walls -RRB-	17858
@NP	a Plexiglas runway	17858
@NP	80 x 10 cm	17878
@NP	80	17878
@NP	10 cm	17883
@NP	10 cm high walls	17895
@NP	its walking surface covered by a thin layer of paraffin oil	17918
@NP	its walking surface	17918
@NP	a thin layer of paraffin oil	17949
@NP	a thin layer	17949
@NP	paraffin oil	17965
@NP	this surface	17982
@NP	forward propulsion	17996
@NP	stationary walking	18031
@NP	rats	18056
@NP	movements	18080
@NP	their forelimbs	18095
@NP	the amount of sensory feedback to the hindlimbs from passive sliding	18123
@NP	the amount	18123
@NP	sensory feedback to the hindlimbs from passive sliding	18137
@NP	sensory feedback	18137
@NP	the hindlimbs from passive sliding	18157
@NP	the hindlimbs	18157
@NP	passive sliding	18176
@NP	passive	18176
@NP	Events where forelimb and hindlimb movements occurred in a stepping sequence	18205
@NP	Events	18205
@NP	forelimb and hindlimb movements	18218
@NP	a stepping sequence	18262
@NP	The test	18295
@NP	9 weeks after transection and only in animals with BBB scores of 6	18326
@NP	9 weeks	18326
@NP	transection	18340
@NP	animals with BBB scores of 6	18364
@NP	animals	18364
@NP	BBB scores of 6	18377
@NP	BBB scores	18377
@NP	6	18391
@NP	the influence of increased sensory feedback	18413
@NP	the influence	18413
@NP	increased sensory feedback	18430
@NP	the rats	18458
@NP	a rough carpet	18482
@NP	the forelimb/hindlimb couplings	18502
@NP	open-field locomotion	18568
@NP	This test	18591
@NP	9 weeks	18623
@NP	transection	18637
@NP	all animals	18650
@NP	the carpet	18677
@NP	Sensory testing Each rat	18689
@NP	Sensory testing	18689
@NP	Each rat	18705
@NP	a towel	18729
@NP	its covered head	18756
@NP	the hindlimbs	18796
@NP	the rats	18836
@NP	they	18884
@NP	five different locations	18908
@NP	dermatomes	18936
@NP	their ascending projections	18957
@NP	the tail , skin	19000
@NP	the tail	19000
@NP	skin	19010
@NP	the femur on both hindlegs , and the dorsal surfaces of both hindpaws	19021
@NP	the femur on both hindlegs	19021
@NP	the femur	19021
@NP	both hindlegs	19034
@NP	the dorsal surfaces of both hindpaws	19053
@NP	the dorsal surfaces	19053
@NP	both hindpaws	19076
@NP	a set of von Frey hairs -LRB- Stoelting , Wood Dale , IL -RRB-	19112
@NP	a set	19112
@NP	von Frey hairs -LRB- Stoelting , Wood Dale , IL -RRB-	19121
@NP	von Frey hairs	19121
@NP	Stoelting	19137
@NP	Wood Dale	19148
@NP	IL	19159
@NP	The von Frey hair	19164
@NP	the skin and pressure applied -LRB- target force , 0.04 -- 1 g -RRB-	19196
@NP	the skin and pressure	19196
@NP	target	19227
@NP	force , 0.04 -- 1 g	19234
@NP	force	19234
@NP	0.04	19241
@NP	1 g	19246
@NP	it	19260
@NP	The stimulation	19313
@NP	a low intensity -LRB- small hair diameter ; 0.04 g target force -RRB-	19342
@NP	a low intensity	19342
@NP	small hair diameter ; 0.04 g target force	19359
@NP	small hair diameter	19359
@NP	0.04 g target force	19380
@NP	three times	19418
@NP	no	19434
@NP	response	19444
@NP	the next thicker hair	19467
@NP	The lowest stimulation intensity to produce a response	19499
@NP	The lowest stimulation intensity	19499
@NP	a response	19543
@NP	three times	19567
@NP	the sensation threshold	19586
@NP	Repeated stimulations of any given spot	19624
@NP	Repeated stimulations	19624
@NP	any given spot	19649
@NP	at least 2 min	19682
@NP	desensitization	19706
@NP	Tracing and histology	19723
@NP	10 weeks	19748
@NP	injury , the corticospinal tract -LRB- CST -RRB- and reticulospinal tract	19763
@NP	injury	19763
@NP	the corticospinal tract -LRB- CST -RRB-	19771
@NP	reticulospinal tract	19805
@NP	RtST	19827
@NP	Hypnorm/Midazolam anesthesia -LRB- as described above -RRB-	19864
@NP	Hypnorm/Midazolam anesthesia	19864
@NP	the CST	19919
@NP	2 µl	19936
@NP	biotinylated dextran amine -LRB- BDA -RRB-	19944
@NP	biotinylated dextran amine	19944
@NP	BDA	19972
@NP	molecular weight -LRB- MW -RRB- , 10,000	19978
@NP	molecular weight	19978
@NP	MW	19996
@NP	10,000	20001
@NP	D-1956 , 10 % in 0.01 M PBS	20009
@NP	D-1956	20009
@NP	10 % in 0.01 M PBS	20017
@NP	10 %	20017
@NP	0.01 M PBS	20024
@NP	Molecular Probes , Eugene	20036
@NP	Molecular Probes	20036
@NP	Eugene	20054
@NP	OR	20062
@NP	four sites	20085
@NP	the sensorimotor cortex using a Hamilton syringe as described previously	20099
@NP	the sensorimotor cortex	20099
@NP	a Hamilton syringe	20129
@NP	Fouad	20173
@NP	et al. , 2001	20179
@NP	et al.	20179
@NP	2001	20187
@NP	the RtST	20209
@NP	a long-necked glass microelectrode	20219
@NP	a Hamilton syringe	20267
@NP	the giant nucleus of the reticular formation	20318
@NP	the giant nucleus	20318
@NP	the reticular formation	20339
@NP	Paxinos and Watson , 1986	20381
@NP	Paxinos and Watson	20381
@NP	1986	20401
@NP	A volume of 0.35 µl 5 % Micro Ruby	20408
@NP	A volume of 0.35 µl 5 %	20408
@NP	A volume	20408
@NP	0.35 µl 5 %	20420
@NP	0.35 µl	20420
@NP	Micro Ruby	20431
@NP	dextran , tetramethylrhodamine , and biotin ; 3000 MW ; Molecular Probes	20443
@NP	dextran , tetramethylrhodamine , and biotin	20443
@NP	3000 MW ; Molecular Probes	20486
@NP	3000 MW	20486
@NP	Molecular Probes	20495
@NP	a period of 5 min	20538
@NP	a period	20538
@NP	5 min	20550
@NP	Two weeks after the tracing , the animals	20557
@NP	Two weeks	20557
@NP	the tracing , the animals	20573
@NP	the tracing	20573
@NP	the animals	20586
@NP	pentobarbital -LRB- Euthanyl , Bimeda-MTC ; 70 mg/100 mg body weight -RRB-	20615
@NP	pentobarbital	20615
@NP	Euthanyl , Bimeda-MTC ; 70 mg/100 mg body weight	20630
@NP	Euthanyl , Bimeda-MTC	20630
@NP	70 mg/100 mg body weight	20652
@NP	70 mg/100	20652
@NP	mg body weight	20662
@NP	phosphate-buffered 4 % paraformaldehyde -LRB- 0.1 M , pH7 .4 -RRB-	20711
@NP	phosphate-buffered 4 % paraformaldehyde	20711
@NP	0.1 M , pH7 .4	20751
@NP	0.1 M	20751
@NP	pH7 .4	20758
@NP	Takami	20766
@NP	et al. , 2002	20773
@NP	et al.	20773
@NP	2002	20781
@NP	The spinal cord and brain	20788
@NP	The spinal cord	20788
@NP	brain	20808
@NP	overnight in the same fixative	20841
@NP	overnight	20841
@NP	the same fixative	20854
@NP	4 °C	20875
@NP	The spinal cords	20880
@NP	a surgical microscope for continuity of the bridge and the spinal cord	20917
@NP	a surgical microscope	20917
@NP	continuity of the bridge and the spinal cord	20943
@NP	continuity	20943
@NP	the bridge and the spinal cord	20957
@NP	the bridge	20957
@NP	the spinal cord	20972
@NP	A 1-mm-thick transverse slice	21006
@NP	the middle of the SC bridge	21051
@NP	the middle	21051
@NP	the SC bridge	21065
@NP	2 % glutaraldehyde	21093
@NP	100 mM sucrose	21116
@NP	phosphate buffer -LRB- PB ; 0.05 M , pH7 .4 -RRB- for at least 24 h	21134
@NP	phosphate buffer -LRB- PB ; 0.05 M , pH7 .4 -RRB-	21134
@NP	phosphate buffer	21134
@NP	PB ; 0.05 M , pH7 .4	21152
@NP	PB	21152
@NP	0.05 M , pH7 .4	21156
@NP	0.05 M	21156
@NP	pH7 .4	21164
@NP	at least 24 h	21175
@NP	4 °C	21192
@NP	This tissue	21197
@NP	1 %	21235
@NP	osmium tetroxide	21247
@NP	2	21268
@NP	16 h , dehydrated ,	21270
@NP	16 h	21270
@NP	Epon-Araldite -LRB- Electron Microscopy Sciences , Fort Washington , PA -RRB-	21300
@NP	Epon-Araldite	21300
@NP	Electron Microscopy Sciences , Fort Washington , PA	21315
@NP	Electron Microscopy Sciences	21315
@NP	Fort Washington	21345
@NP	PA	21362
@NP	semithin sections -LRB- 1 µm -RRB-	21391
@NP	semithin sections	21391
@NP	1 µm	21410
@NP	These sections	21417
@NP	a 1 % toluidine blue -- 1 % methylene blue --	21450
@NP	a 1 % toluidine blue	21450
@NP	1 % methylene blue	21470
@NP	1 % sodium borate solution	21488
@NP	1 %	21488
@NP	sodium borate solution	21491
@NP	SC bridge histology	21525
@NP	the number of myelinated axons and blood vessels	21562
@NP	the number	21562
@NP	myelinated axons and blood vessels	21576
@NP	The remaining SC bridge and adjacent rostral and caudal spinal cord and brain	21620
@NP	The remaining SC bridge	21620
@NP	adjacent rostral and caudal spinal cord	21648
@NP	brain	21692
@NP	30 % sucrose	21720
@NP	PB -LRB- 0.1 M , pH 7.4 -RRB-	21735
@NP	PB	21735
@NP	0.1 M	21739
@NP	pH 7.4	21746
@NP	at least 24 h	21758
@NP	Tissue-Tek OCT compound	21783
@NP	Sakura Finetek	21808
@NP	Torrance	21824
@NP	CA	21834
@NP	30-µm-thick sagittal sections	21852
@NP	Efficacy of the tracing	21883
@NP	Efficacy	21883
@NP	the tracing	21895
@NP	cervical cord sections	21924
@NP	Total numbers of myelinated axons and blood vessels	21948
@NP	Total numbers	21948
@NP	myelinated axons and blood vessels	21965
@NP	Xu et al. , 1995b	22038
@NP	Xu	22038
@NP	et al.	22041
@NP	1995b	22049
@NP	1-µm-thick transverse plastic sections	22078
@NP	three sections	22118
@NP	a 1 mm slice from the center of the SC bridge ; n = 6	22138
@NP	a 1 mm slice	22138
@NP	the center of the SC bridge ; n = 6	22156
@NP	the center of the SC bridge	22156
@NP	the center	22156
@NP	the SC bridge	22170
@NP	n = 6	22185
@NP	n	22185
@NP	6	22189
@NP	group	22195
@NP	the bridge area	22203
@NP	a fractionator grid	22255
@NP	630X magnification	22278
@NP	optical fractionator method ; West and Collins , 1989	22298
@NP	optical fractionator method	22298
@NP	West and Collins , 1989	22327
@NP	West and Collins	22327
@NP	1989	22345
@NP	Every blood vessel	22352
@NP	every myelinated axon present within each grid square	22375
@NP	every myelinated axon	22375
@NP	each grid square	22412
@NP	surface area , 0.028 mm2	22430
@NP	surface area	22430
@NP	0.028 mm2	22444
@NP	Immunohistochemistry The sections chosen for evaluation	22468
@NP	Immunohistochemistry	22468
@NP	The sections	22489
@NP	evaluation	22513
@NP	a second time on the slides	22539
@NP	a second time	22539
@NP	the slides	22556
@NP	4 % paraformaldehyde , 0.1 % glutaraldehyde , and 0.1 % picric acid	22572
@NP	4 % paraformaldehyde	22572
@NP	0.1 % glutaraldehyde	22593
@NP	0.1 % picric acid	22618
@NP	20 min	22639
@NP	0.1 M PB three times	22665
@NP	0.1 M PB	22665
@NP	three times	22674
@NP	A quenching step	22687
@NP	the sections	22725
@NP	10 min	22742
@NP	50 % EtOH plus 0.3 % H2O2 , followed by two washing cycles in PB for 10 min	22752
@NP	50 % EtOH	22752
@NP	0.3 % H2O2 , followed by two washing cycles in PB for 10 min	22766
@NP	0.3 % H2O2	22766
@NP	two	22789
@NP	cycles	22801
@NP	PB for 10 min	22811
@NP	PB	22811
@NP	10 min	22818
@NP	Blocking	22826
@NP	0.4 % NaBH4 for 10 min	22854
@NP	0.4 % NaBH4	22854
@NP	10 min	22869
@NP	the slides	22891
@NP	PB three times for 20 min	22905
@NP	PB	22905
@NP	three times	22908
@NP	20 min	22924
@NP	they	22932
@NP	0.1 M citrate buffer , pH 4.5 ,	22957
@NP	0.1 M citrate buffer	22957
@NP	pH 4.5	22979
@NP	4 °C	23000
@NP	The next day	23005
@NP	the slides	23019
@NP	room temperature	23045
@NP	1 min	23081
@NP	600 W , followed by two cycles of 30 s at 600	23090
@NP	600 W	23090
@NP	two cycles of 30 s at 600	23109
@NP	two cycles	23109
@NP	30 s at 600	23123
@NP	30 s	23123
@NP	600	23131
@NP	Watts in a separate glass container in 200 ml of H2O	23135
@NP	Watts	23135
@NP	a separate glass container in 200 ml of H2O	23144
@NP	a separate glass container	23144
@NP	200 ml of H2O	23174
@NP	200 ml	23174
@NP	H2O	23184
@NP	Slides	23189
@NP	30 min	23218
@NP	1 %	23258
@NP	Top Block gelatin	23261
@NP	Juro Supply	23280
@NP	Lucerne	23293
@NP	Switzerland	23302
@NP	20 min -LSB- 200 mg of Top Block in 0.3 % Tris-buffered saline with Triton X-100	23319
@NP	20 min	23319
@NP	200 mg of Top Block in 0.3 % Tris-buffered saline with Triton X-100	23327
@NP	200 mg	23327
@NP	Top Block in 0.3 % Tris-buffered saline with Triton X-100	23337
@NP	Top Block	23337
@NP	0.3 % Tris-buffered saline with Triton X-100	23350
@NP	0.3 % Tris-buffered saline	23350
@NP	Triton X-100	23381
@NP	TBS-TX	23395
@NP	The 5-HT antibody -LRB- DiaSorin , Stillwater , MN -RRB-	23405
@NP	The 5-HT antibody	23405
@NP	DiaSorin	23424
@NP	Stillwater	23434
@NP	MN	23446
@NP	a dilution of 1:8000	23463
@NP	a dilution	23463
@NP	1:8000	23477
@NP	4 % normal goat serum -LRB- NGS -RRB-	23495
@NP	4 % normal goat serum	23495
@NP	NGS	23517
@NP	the slides overnight at 4 °C	23534
@NP	the slides overnight	23534
@NP	4 °C	23558
@NP	Slides	23563
@NP	PB for 10 min	23591
@NP	PB	23591
@NP	10 min	23598
@NP	the second	23612
@NP	goat	23636
@NP	anti rabbit antibody -LRB- 1:300 in 0.3 % TBS-TX plus 2 % NGS -RRB-	23641
@NP	anti rabbit antibody	23641
@NP	1:300 in 0.3 % TBS-TX plus 2 % NGS	23663
@NP	1:300	23663
@NP	0.3 % TBS-TX plus 2 % NGS	23672
@NP	0.3 % TBS-TX	23672
@NP	2 % NGS	23689
@NP	45 min at room temperature	23720
@NP	45 min	23720
@NP	room temperature	23730
@NP	Slides	23748
@NP	PBS for 10 min	23781
@NP	PBS	23781
@NP	10 min	23789
@NP	the ABC elite complex	23801
@NP	45 min	23837
@NP	three washing steps of 10 min each in PBS	23851
@NP	three	23851
@NP	steps of 10 min each	23865
@NP	steps	23865
@NP	10 min each	23874
@NP	10 min	23874
@NP	each	23881
@NP	PBS	23889
@NP	they	23894
@NP	0.05 M Tris , pH 8.0 ,	23922
@NP	0.05 M Tris	23922
@NP	pH 8.0	23935
@NP	5 min	23947
@NP	Slides	23954
@NP	50 ml of 0.05 MTris plus 25mgofDABplus 25µl of 30 % H2O2 for ≈ 1 -- 2 min	23982
@NP	50 ml of 0.05 MTris plus 25mgofDABplus 25µl of 30 % H2O2 for ≈ 1	23982
@NP	50 ml of 0.05 MTris	23982
@NP	50 ml	23982
@NP	0.05 MTris	23991
@NP	25mgofDABplus 25µl of 30 % H2O2 for ≈ 1	24006
@NP	25mgofDABplus 25µl	24006
@NP	30 % H2O2 for ≈ 1	24028
@NP	30 % H2O2	24028
@NP	≈ 1	24040
@NP	2 min	24043
@NP	The reaction	24050
@NP	ice-cold PBS	24078
@NP	two washes in PB for 10 min and one rinse in water	24104
@NP	two washes	24104
@NP	PB for 10 min and one rinse in water	24118
@NP	PB for 10 min	24118
@NP	PB	24118
@NP	10 min	24125
@NP	one rinse in water	24136
@NP	one rinse	24136
@NP	water	24149
@NP	Slides	24156
@NP	5-HT fiber counts The number of 5-HT-positive fibers caudal to the lesion site	24202
@NP	5-HT fiber	24202
@NP	The number of 5-HT-positive fibers	24220
@NP	The number	24220
@NP	5-HT-positive fibers	24234
@NP	the lesion site	24265
@NP	a light microscope	24315
@NP	bright-field illumination	24339
@NP	a final magnification of 400X	24368
@NP	a final magnification	24368
@NP	400X	24393
@NP	25 µm	24419
@NP	sagittal sections	24425
@NP	CST and RtST fibers	24465
@NP	CST	24465
@NP	RtST fibers	24473
@NP	spare sections	24493
@NP	the sections chosen for the analysis of 5-HT-positive fibers	24509
@NP	the sections	24509
@NP	the analysis of 5-HT-positive fibers	24533
@NP	the analysis	24533
@NP	5-HT-positive fibers	24549
@NP	75 µm intervals	24588
@NP	This	24605
@NP	the possibility of counting the same fiber twice	24620
@NP	the possibility	24620
@NP	the same fiber	24648
@NP	each	24673
@NP	these remaining sections -LRB- an average of ≈ 11 sections per animal -RRB-	24681
@NP	these remaining sections	24681
@NP	an average of ≈ 11 sections per animal	24707
@NP	an average	24707
@NP	≈ 11 sections per animal	24721
@NP	≈ 11 sections	24721
@NP	animal	24738
@NP	all fibers in the caudal spinal cord with a length of > 100 µm	24747
@NP	all fibers	24747
@NP	the caudal spinal cord with a length of > 100 µm	24761
@NP	the caudal spinal cord	24761
@NP	a length of > 100 µm	24789
@NP	a length	24789
@NP	> 100 µm	24801
@NP	>	24801
@NP	100 µm	24802
@NP	Corticospinal and reticulospinal tract staining Sections	24823
@NP	Corticospinal	24823
@NP	reticulospinal tract staining Sections	24841
@NP	a fluorescent microscope	24906
@NP	labeling	24941
@NP	Micro Ruby	24955
@NP	all animals	24970
@NP	fibers	24983
@NP	rostral	25004
@NP	the lesions	25015
@NP	some cases	25035
@NP	the bridge	25050
@NP	Sections	25062
@NP	avidin-HRP	25096
@NP	ABC Elite	25108
@NP	Vector Laboratories , Burlingame , CA	25119
@NP	Vector Laboratories	25119
@NP	Burlingame , CA	25140
@NP	a nickel-enhanced diaminobenzidine HRP reaction	25168
@NP	the visualization of the BDA tracer	25220
@NP	the visualization	25220
@NP	the BDA tracer	25241
@NP	a semifree-floating technique	25260
@NP	Herzog and Brosamle	25315
@NP	1997	25336
@NP	both CST and RtST fibers	25351
@NP	both CST	25351
@NP	RtST fibers	25364
@NP	the caudal end of the bridge	25391
@NP	the caudal end	25391
@NP	the bridge	25409
@NP	the caudal stump of the spinal cord	25426
@NP	the caudal stump	25426
@NP	the spinal cord	25446
@NP	no additional analysis	25463
@NP	Statistics	25501
@NP	statistical analysis	25519
@NP	exclusion criteria	25541
@NP	an attempt	25576
@NP	the variability in the groups	25597
@NP	the variability	25597
@NP	the groups	25616
@NP	animals	25628
@NP	a spinal cord stump -LRB- rostral or caudal -RRB-	25645
@NP	a spinal cord stump	25645
@NP	rostral or caudal	25666
@NP	rostral	25666
@NP	caudal	25677
@NP	the channel	25703
@NP	the injection of the OEG	25719
@NP	the injection	25719
@NP	the OEG	25736
@NP	inflammation	25752
@NP	a lesion that was larger than 50 % of the spinal cord	25782
@NP	a lesion	25782
@NP	50 % of the spinal cord	25812
@NP	50 %	25812
@NP	the spinal cord	25819
@NP	Statistical comparisons	25836
@NP	GraphPad Prism	25881
@NP	Comparisons between the treatment groups	25897
@NP	Comparisons	25897
@NP	the treatment groups	25917
@NP	the Mann -- Whitney U test	25954
@NP	the Mann	25954
@NP	Whitney U test	25964
@NP	Whitney U	25964
@NP	test	25974
@NP	Differences of p 0.05	25980
@NP	Differences	25980
@NP	p 0.05	25995
@NP	p 0.01	26031
@NP	Errors	26074
@NP	SEM	26094
@NP	Results Figure 1 .	26100
@NP	Results	26100
@NP	Figure 1	26108
@NP	Experimental design	26118
@NP	the cell grafting and cABC treatment	26142
@NP	the removal of the thoracic 8 segment of the spinal cord	26185
@NP	the removal	26185
@NP	the thoracic 8 segment of the spinal cord	26200
@NP	the thoracic 8 segment	26200
@NP	8	26213
@NP	the spinal cord	26226
@NP	Figure 2 .	26244
@NP	Figure	26244
@NP	2	26251
@NP	Effectiveness of cABC application	26254
@NP	Effectiveness	26254
@NP	cABC application	26271
@NP	the use of antibodies against either intact -LRB- 1D1 , CS-56 -RRB-	26307
@NP	the use	26307
@NP	antibodies against either intact -LRB- 1D1 , CS-56 -RRB-	26318
@NP	antibodies	26318
@NP	intact	26344
@NP	1D1 , CS-56	26352
@NP	1D1	26352
@NP	CS-56	26357
@NP	2B6	26377
@NP	chondroitin sulfate	26382
@NP	p < 0.05 .	26404
@NP	p	26404
@NP	< 0.05 .	26405
@NP	<	26405
@NP	0.05 .	26406
@NP	Figure 3 .	26413
@NP	Figure	26413
@NP	3	26420
@NP	Comparison	26423
@NP	the open-field locomotion scores between the different treatment groups	26437
@NP	the open-field locomotion scores	26437
@NP	the different treatment groups	26478
@NP	the BBB score -LRB- A -RRB-	26525
@NP	the BBB score	26525
@NP	A	26541
@NP	the percentage of successful forelimb / hindlimb coupling -LRB- B -RRB-	26557
@NP	the percentage	26557
@NP	successful forelimb / hindlimb coupling -LRB- B -RRB-	26575
@NP	successful forelimb / hindlimb coupling	26575
@NP	successful forelimb	26575
@NP	hindlimb coupling	26596
@NP	B	26616
@NP	C , The time course of recovery	26620
@NP	C	26620
@NP	The time course of recovery	26623
@NP	The time course	26623
@NP	recovery	26642
@NP	treatment-induced benefits	26657
@NP	8 weeks	26712
@NP	surgery	26726
@NP	The dots	26735
@NP	the scores of single animals	26754
@NP	the scores	26754
@NP	single animals	26768
@NP	p < 0.05 , ** p < 0.01 .	26785
@NP	p	26785
@NP	< 0.05 , ** p < 0.01 .	26786
@NP	<	26786
@NP	0.05 , ** p < 0.01 .	26787
@NP	0.05	26787
@NP	p < 0.01 .	26795
@NP	p	26795
@NP	< 0.01 .	26796
@NP	<	26796
@NP	0.01 .	26797
@NP	Figure 4 .	26804
@NP	Figure	26804
@NP	4	26811
@NP	Video sequence from a rat	26814
@NP	Video sequence	26814
@NP	a rat	26834
@NP	OEG and Schwann cell grafts	26853
@NP	cABC	26897
@NP	the range of leg motion	26908
@NP	the range	26908
@NP	leg motion	26921
@NP	the alternation between the forelimb and hindlimb movements	26943
@NP	the alternation	26943
@NP	the forelimb and hindlimb movements	26967
@NP	The panels	27004
@NP	rows	27032
@NP	right	27050
@NP	Figure 5 .	27058
@NP	Figure	27058
@NP	5	27065
@NP	Sensory testing using von Frey hairs at the base of the tail	27068
@NP	Sensory testing	27068
@NP	von Frey hairs at the base of the tail	27090
@NP	von Frey hairs	27090
@NP	the base of the tail	27108
@NP	the base	27108
@NP	the tail	27120
@NP	increased responsiveness in all of the treated groups	27135
@NP	increased responsiveness	27135
@NP	all of the treated groups	27163
@NP	all	27163
@NP	the treated groups	27170
@NP	p < 0.05 .	27191
@NP	p	27191
@NP	< 0.05 .	27192
@NP	<	27192
@NP	0.05 .	27193
@NP	Figure 6 .	27200
@NP	Figure	27200
@NP	6	27207
@NP	A	27210
@NP	5-HT-positive fibers	27213
@NP	the caudal spinal cord	27258
@NP	The quantification of these fibers in the caudal spinal cord	27282
@NP	The quantification	27282
@NP	these fibers in the caudal spinal cord	27304
@NP	these fibers	27304
@NP	the caudal spinal cord	27320
@NP	B.	27361
@NP	C	27381
@NP	there	27384
@NP	no correlation between individual functional recovery	27394
@NP	no correlation	27394
@NP	individual functional recovery	27417
@NP	the number of 5-HT-positive fibers in the caudal spinal cord	27452
@NP	the number	27452
@NP	5-HT-positive fibers in the caudal spinal cord	27466
@NP	5-HT-positive fibers	27466
@NP	the caudal spinal cord	27490
@NP	p < 0.05 .	27515
@NP	p	27515
@NP	< 0.05 .	27516
@NP	<	27516
@NP	0.05 .	27517
@NP	Figure 7 .	27524
@NP	Figure	27524
@NP	7	27531
@NP	Significantly greater numbers of peripheral-myelinated axons -LRB- arrow -RRB-	27534
@NP	Significantly greater numbers of peripheral-myelinated axons	27534
@NP	Significantly greater numbers	27534
@NP	peripheral-myelinated axons	27567
@NP	arrow	27596
@NP	the Schwann cell bridge	27622
@NP	digestion of CSPGs with chondroitinase ABC	27652
@NP	digestion	27652
@NP	CSPGs with chondroitinase ABC	27665
@NP	CSPGs	27665
@NP	chondroitinase ABC	27676
@NP	Animals with grafts only -LRB- A -RRB- and animals with grafts and cABC	27696
@NP	Animals with grafts only -LRB- A -RRB-	27696
@NP	Animals	27696
@NP	grafts only -LRB- A -RRB-	27709
@NP	grafts only	27709
@NP	grafts	27709
@NP	A	27723
@NP	animals with grafts and cABC	27730
@NP	animals	27730
@NP	grafts and cABC	27743
@NP	B	27761
@NP	Scale bar , 150µm .	27775
@NP	Scale bar	27775
@NP	150µm	27786
@NP	Figure 8 .	27794
@NP	Figure	27794
@NP	8	27801
@NP	Counts of myelinated axons in the middle of the bridge	27804
@NP	Counts	27804
@NP	myelinated axons in the middle of the bridge	27814
@NP	myelinated axons	27814
@NP	the middle of the bridge	27834
@NP	the middle	27834
@NP	the bridge	27848
@NP	a significant -LRB- p < 0.01 -RRB- increase -LRB- A -RRB-	27866
@NP	a significant -LRB- p < 0.01 -RRB- increase	27866
@NP	p < 0.01	27882
@NP	p	27882
@NP	< 0.01	27883
@NP	<	27883
@NP	0.01	27885
@NP	A	27902
@NP	the group	27908
@NP	grafts and cABC	27923
@NP	B , The number of blood vessels in the bridge	27940
@NP	B	27940
@NP	The number of blood vessels in the bridge	27943
@NP	The number	27943
@NP	blood vessels in the bridge	27957
@NP	blood vessels	27957
@NP	the bridge	27974
@NP	the groups	28011
@NP	C	28023
@NP	There	28026
@NP	a significant correlation -LRB- r2 = 0.63 -RRB-	28036
@NP	a significant correlation	28036
@NP	r2	28063
@NP	0.63	28067
@NP	individual functional recovery	28081
@NP	the number of myelinated axons	28116
@NP	the number	28116
@NP	myelinated axons	28130
@NP	cABC	28149
@NP	chondroitin sulfate	28163
@NP	injured spinal cord	28186
@NP	Two weeks	28206
@NP	spinal cord transection	28222
@NP	tissue from three animals with grafts	28247
@NP	tissue	28247
@NP	three animals with grafts	28259
@NP	three animals	28259
@NP	grafts	28278
@NP	two	28289
@NP	cABC	28312
@NP	cABC	28351
@NP	chondroitin sulfate	28369
@NP	Three monoclonal antibodies	28390
@NP	digested or intact chondroitin sulfate	28440
@NP	an increase of 2B6	28490
@NP	an increase	28490
@NP	2B6	28505
@NP	CS-56 and 1D1 immunoreactivity at the caudal SC/spinal cord interface	28521
@NP	CS-56	28521
@NP	1D1 immunoreactivity at the caudal SC/spinal cord interface	28531
@NP	1D1 immunoreactivity	28531
@NP	the caudal SC/spinal cord interface	28555
@NP	cABC efficacy	28601
@NP	The average values of staining intensity	28616
@NP	The average values	28616
@NP	staining intensity	28638
@NP	Neurocan -LRB- 1D1 -RRB-	28678
@NP	89.6 ± 5.1 -LRB- SEM -RRB- and 70.3 ± 4.4	28694
@NP	89.6 ± 5.1 -LRB- SEM -RRB-	28694
@NP	89.6 ±	28694
@NP	5.1 -LRB- SEM -RRB-	28699
@NP	70.3 ± 4.4	28713
@NP	70.3 ±	28713
@NP	4.4	28720
@NP	chondroitin sulfate proteoglycans	28729
@NP	CS56	28764
@NP	69.8 ± 8.6 and 50.7 ± 5.3	28771
@NP	degraded chondroitin sulfate proteoglycans , 10 ± 0.6 and 16.2	28802
@NP	degraded chondroitin sulfate proteoglycans	28802
@NP	10 ± 0.6 and 16.2	28846
@NP	10 ±	28846
@NP	0.6 and 16.2	28849
@NP	± 1.1	28861
@NP	the controls and the cABC-treated rats , respectively -LRB- Fig. 2 -RRB-	28869
@NP	the controls and the cABC-treated rats , respectively	28869
@NP	the controls and the cABC-treated rats	28869
@NP	the controls	28869
@NP	the cABC-treated rats	28886
@NP	Fig. 2	28923
@NP	Partial locomotor recovery	28932
@NP	combined treatment	28968
@NP	the spinal cord transection	29004
@NP	all animals	29033
@NP	complete , flaccid paralysis of the hindlimbs	29055
@NP	complete , flaccid paralysis	29055
@NP	the hindlimbs	29086
@NP	Slight recovery	29101
@NP	spontaneous movements of up to two joints of the hindlegs	29133
@NP	spontaneous movements	29133
@NP	up to two joints of the hindlegs	29158
@NP	up to two joints	29158
@NP	the hindlegs	29178
@NP	the next 5 weeks	29207
@NP	injury -LRB- Fig. 3C -RRB-	29230
@NP	injury	29230
@NP	Fig. 3C	29238
@NP	Rhythmic limb movements	29248
@NP	6 weeks	29297
@NP	the extensive laminectomy	29333
@NP	many animals	29360
@NP	severe lordosis	29387
@NP	a hunched posture rostral to the laminectomy site	29418
@NP	a hunched posture rostral	29418
@NP	the laminectomy site	29447
@NP	Some rats	29469
@NP	signs of spasticity	29494
@NP	signs	29494
@NP	spasticity	29503
@NP	asymmetric muscle tone resulting in asymmetric body posture	29525
@NP	asymmetric muscle tone	29525
@NP	asymmetric body posture	29561
@NP	spasticity	29591
@NP	a subjective ranking score	29623
@NP	0 , no sign of spasticity ,	29664
@NP	0	29664
@NP	no sign of spasticity	29667
@NP	no sign	29667
@NP	spasticity	29678
@NP	3 , extensive spasticity	29693
@NP	3	29693
@NP	extensive spasticity	29696
@NP	no difference	29719
@NP	groups -LRB- data not shown -RRB-	29751
@NP	groups	29751
@NP	data not shown	29759
@NP	data	29759
@NP	Both lordosis and spasticity	29776
@NP	locomotor ability	29814
@NP	the animal 's functional recovery	29857
@NP	the animal 's	29857
@NP	the ablation of descending axons	29907
@NP	the ablation	29907
@NP	descending axons	29923
@NP	One unexpected finding	29941
@NP	some treated rats	29973
@NP	movements of the hindlegs	30026
@NP	movements	30026
@NP	the hindlegs	30039
@NP	phases when the animals were standing	30059
@NP	phases	30059
@NP	the animals	30071
@NP	the forelimbs	30101
@NP	This	30129
@NP	spontaneous activity	30158
@NP	the pattern generating networks in the lumbar spinal cord	30182
@NP	the pattern	30182
@NP	networks in the lumbar spinal cord	30205
@NP	networks	30205
@NP	the lumbar spinal cord	30217
@NP	These sequences	30241
@NP	the evaluation of open-field locomotion	30276
@NP	the evaluation	30276
@NP	open-field locomotion	30294
@NP	the BBB rating scale	30322
@NP	none	30347
@NP	the animals	30355
@NP	the spinal cords	30372
@NP	the channels	30403
@NP	one animal -LRB- grafts only -RRB-	30424
@NP	one animal	30424
@NP	grafts	30436
@NP	the rostral injection of OEG	30450
@NP	the rostral injection	30450
@NP	OEG	30475
@NP	strong inflammation and tissue destruction	30491
@NP	a second lesion rostral	30544
@NP	the transection spanning ≈ 80 % of the spinal cord	30571
@NP	the transection	30571
@NP	≈ 80 % of the spinal cord	30596
@NP	≈ 80 %	30596
@NP	the spinal cord	30604
@NP	this	30629
@NP	the exclusion criteria	30644
@NP	this animal	30668
@NP	the study	30697
@NP	Open-field locomotor score Behavioral testing	30708
@NP	Open-field locomotor score	30708
@NP	Behavioral testing	30735
@NP	9 weeks postlesion -LRB- Fig. 3A -RRB-	30774
@NP	9 weeks postlesion	30774
@NP	9 weeks	30774
@NP	postlesion	30782
@NP	Fig. 3A	30794
@NP	The average score in the control group -LRB- n = 8 -RRB-	30804
@NP	The average score in the control group	30804
@NP	The average score	30804
@NP	the control group	30825
@NP	n	30844
@NP	8	30846
@NP	2.1 ± 0.7 -LRB- SEM -RRB-	30853
@NP	2.1 ± 0.7	30853
@NP	SEM	30862
@NP	the group	30871
@NP	transplants	30886
@NP	4 ± 0.6 -LRB- n = 6 -RRB-	30902
@NP	4 ± 0.6	30902
@NP	n	30909
@NP	6	30911
@NP	the cABC group	30922
@NP	6.6 ± 0.7 -LRB- n = 5 -RRB-	30941
@NP	6.6 ± 0.7	30941
@NP	n	30950
@NP	5	30952
@NP	The average BBB score of the cABC group	30956
@NP	The average BBB score	30956
@NP	the cABC group	30981
@NP	that of the other groups -LRB- p < 0.01 -RRB-	31026
@NP	that	31026
@NP	the other groups -LRB- p < 0.01 -RRB-	31034
@NP	the other groups	31034
@NP	p < 0.01	31053
@NP	p	31053
@NP	< 0.01	31054
@NP	<	31054
@NP	0.01	31055
@NP	The group with the transplants	31062
@NP	The group	31062
@NP	the transplants	31077
@NP	any significant improvements	31109
@NP	the BBB score	31141
@NP	the control group	31174
@NP	No significant difference between the cABC and control groups	31193
@NP	No significant difference	31193
@NP	the cABC and control groups	31227
@NP	8 weeks	31270
@NP	injury -LRB- Fig. 3C -RRB-	31284
@NP	injury	31284
@NP	Fig. 3C	31292
@NP	the 7 weeks after injury	31309
@NP	the 7 weeks	31309
@NP	injury	31327
@NP	the BBB scores	31335
@NP	0 and 4 points	31365
@NP	The first signs of recovery in locomotor functions	31381
@NP	The first signs	31381
@NP	recovery in locomotor functions	31400
@NP	recovery	31400
@NP	locomotor functions	31412
@NP	the cABC group and the rats	31489
@NP	the cABC group	31489
@NP	the rats	31508
@NP	Matrigel only , at 8 weeks	31522
@NP	Matrigel only	31522
@NP	8 weeks	31540
@NP	The results	31549
@NP	the recovery	31575
@NP	not plateau	31592
@NP	9 weeks	31607
@NP	the injury , the time point at which testing was discontinued	31621
@NP	the injury	31621
@NP	the time point at which testing was discontinued	31633
@NP	the time point	31633
@NP	testing	31657
@NP	A representative walking sequence	31683
@NP	a rat from the cABC group with forelimb and hindlimb activity	31720
@NP	a rat	31720
@NP	the cABC group with forelimb and hindlimb activity	31731
@NP	the cABC group	31731
@NP	forelimb and hindlimb activity	31751
@NP	Figure 4	31794
@NP	Forelimb/hindlimb coupling This analysis	31804
@NP	Forelimb/hindlimb coupling	31804
@NP	This analysis	31831
@NP	information	31866
@NP	the tendency of forelimb and hindlimb movements	31881
@NP	the tendency	31881
@NP	forelimb and hindlimb movements	31897
@NP	alternate	31932
@NP	hindlimb coupling	31953
@NP	the BBB score	31988
@NP	animals	32010
@NP	that	32018
@NP	weight-supported plantar stepping	32043
@NP	weight-supported plantar	32043
@NP	animals with lower locomotor capabilities	32090
@NP	animals	32090
@NP	lower locomotor capabilities	32103
@NP	this	32133
@NP	an important outcome measure	32146
@NP	A measure of the frequency of movements and a relation to forelimb stepping	32176
@NP	A measure	32176
@NP	the frequency of movements and a relation to forelimb stepping	32189
@NP	the frequency of movements	32189
@NP	the frequency	32189
@NP	movements	32206
@NP	a relation to forelimb stepping	32220
@NP	a relation	32220
@NP	forelimb stepping	32234
@NP	forelimb	32234
@NP	complete SCI	32279
@NP	the percentage of hindlimb steps after forelimb steps	32304
@NP	the percentage	32304
@NP	hindlimb steps after forelimb steps	32322
@NP	hindlimb steps	32322
@NP	forelimb steps	32343
@NP	assessment	32376
@NP	one video recording for each animal at 9 weeks after injury	32388
@NP	one video recording	32388
@NP	each animal at 9 weeks after injury	32412
@NP	each animal	32412
@NP	9 weeks after injury	32427
@NP	9 weeks	32427
@NP	injury	32441
@NP	The results	32458
@NP	Figure 3B	32488
@NP	the open-field locomotor score	32505
@NP	the untreated rats	32537
@NP	the lowest percentage of forelimb/hindlimb coupling	32563
@NP	the lowest percentage	32563
@NP	forelimb/hindlimb coupling	32588
@NP	18.5 ± 0.5 %	32620
@NP	18.5 ±	32620
@NP	This	32633
@NP	the group with grafts only	32671
@NP	the group	32671
@NP	grafts only	32686
@NP	38.3 ± 0.7 %	32699
@NP	38.3	32699
@NP	± 0.7 %	32704
@NP	The best coupling	32713
@NP	the group with grafts and cABC	32746
@NP	the group	32746
@NP	grafts and cABC	32761
@NP	70 ± 3.4 %	32778
@NP	70	32778
@NP	± 3.4 %	32781
@NP	This improvement	32790
@NP	the untreated and the grafted groups	32849
@NP	Role of sensory feedback in hindlimb movement	32887
@NP	Role	32887
@NP	sensory feedback in hindlimb movement	32895
@NP	sensory feedback	32895
@NP	hindlimb movement	32915
@NP	hindlimb movements	32952
@NP	sensory feedback	32988
@NP	the sliding of hindlegs	33020
@NP	the sliding	33020
@NP	hindlegs	33035
@NP	forelimb stepping	33051
@NP	forelimb	33051
@NP	commands	33093
@NP	motor tracts	33121
@NP	we	33135
@NP	locomotion	33147
@NP	three different surfaces	33161
@NP	The first	33187
@NP	a smooth Plexiglas surface used for all open-field testing	33201
@NP	a smooth Plexiglas surface	33201
@NP	all open-field testing	33237
@NP	the second	33261
@NP	a Plexiglas surface	33276
@NP	a thin layer of oil -LRB- referred to as a slippery surface -RRB-	33309
@NP	a thin layer	33309
@NP	oil	33325
@NP	a slippery surface	33345
@NP	the third	33370
@NP	a carpet -LRB- rough surface -RRB-	33384
@NP	a carpet	33384
@NP	rough surface	33394
@NP	None of the groups on the rough surface	33410
@NP	None	33410
@NP	the groups on the rough surface	33418
@NP	the groups	33418
@NP	the rough surface	33432
@NP	the prediction	33470
@NP	cutaneous feedback	33500
@NP	the hindlimbs	33522
@NP	the surface would enhance the hindlimb activity	33554
@NP	the surface	33554
@NP	the hindlimb activity	33580
@NP	the carpet	33611
@NP	friction	33632
@NP	the forelimbs	33642
@NP	propulsion	33678
@NP	this	33694
@NP	a nonquantified , but obvious , increase in walking speed	33711
@NP	a nonquantified , but obvious , increase	33711
@NP	speed	33761
@NP	The forelimb/hindlimb	33768
@NP	score was either reduced -LRB- p < 0.05 in four animals -RRB-	33799
@NP	score was either reduced	33799
@NP	score	33799
@NP	p < 0.05 in four animals	33826
@NP	p	33826
@NP	< 0.05 in four animals	33828
@NP	<	33828
@NP	0.05 in four animals	33830
@NP	0.05	33830
@NP	four animals	33838
@NP	Walking	33880
@NP	the fore limbs	33891
@NP	the slippery runway	33909
@NP	necessary , a slight tilt of the surface	33937
@NP	necessary , a slight tilt	33937
@NP	necessary	33937
@NP	a slight tilt	33948
@NP	the surface	33965
@NP	stationary walking	33990
@NP	The rats	34010
@NP	a rhythmic	34028
@NP	pattern	34048
@NP	the forelimbs	34061
@NP	the rest of the body relative to the surface	34090
@NP	the rest	34090
@NP	the body relative to the surface	34102
@NP	the body	34102
@NP	the surface	34123
@NP	sensory feedback	34160
@NP	the hindlimbs	34180
@NP	these conditions	34201
@NP	it	34219
@NP	the rats	34243
@NP	only very few stepping sequences	34265
@NP	only very few	34265
@NP	sequences	34288
@NP	We	34313
@NP	sequences in which forelimb locomotion was tied to hindlimb activation	34327
@NP	sequences	34327
@NP	forelimb locomotion	34346
@NP	hindlimb activation	34378
@NP	this	34407
@NP	the idea	34426
@NP	forelimbs and hindlimbs	34440
@NP	direct descending control	34480
@NP	locomotion	34532
@NP	Alternating activity of both forelimbs and hindlimbs during stationary walking	34544
@NP	Alternating activity	34544
@NP	both forelimbs and hindlimbs	34568
@NP	stationary walking	34604
@NP	only two of five rats in the cABC group	34636
@NP	only two	34636
@NP	five rats in the cABC group	34648
@NP	five rats	34648
@NP	the cABC group	34661
@NP	no animals in the remaining groups	34683
@NP	no animals	34683
@NP	the remaining groups	34697
@NP	This result	34719
@NP	the idea	34740
@NP	animals with alternating forelimb/hindlimb activity	34757
@NP	animals	34757
@NP	forelimb/hindlimb activity	34782
@NP	a reconnection of the caudal with the rostral spinal cord	34810
@NP	a reconnection	34810
@NP	the caudal with the rostral spinal cord	34828
@NP	the caudal	34828
@NP	the rostral spinal cord	34844
@NP	Cell grafts	34882
@NP	response	34904
@NP	tactile stimuli	34916
@NP	Spinal cord injury	34932
@NP	increased responses	34975
@NP	mechanical stimuli	34998
@NP	cutaneous receptors -LRB- allodynia -RRB-	35020
@NP	cutaneous receptors	35020
@NP	allodynia	35041
@NP	the lesion -LRB- Siddall et al. , 1995 ; Hutchinson et al. , 2004 -RRB-	35058
@NP	the lesion	35058
@NP	Siddall	35070
@NP	et al. , 1995 ; Hutchinson et al. , 2004	35078
@NP	et al.	35078
@NP	1995 ; Hutchinson et al.	35086
@NP	1995	35086
@NP	Hutchinson et al.	35092
@NP	Hutchinson	35092
@NP	et al.	35103
@NP	2004	35111
@NP	the experimental treatments	35134
@NP	these responses	35173
@NP	we	35190
@NP	the reaction	35200
@NP	mechanical stimulation	35216
@NP	calibrated von Frey hairs at five different locations below the lesion	35244
@NP	calibrated von Frey hairs at five different locations	35244
@NP	von Frey hairs at five	35255
@NP	von Frey hairs	35255
@NP	five	35273
@NP	the lesion	35304
@NP	A general finding	35316
@NP	all rats	35346
@NP	the base of the tail	35356
@NP	the base	35356
@NP	the tail	35368
@NP	the most sensitive and most reliably excitable location	35381
@NP	the relation of excitability at the different locations	35446
@NP	the relation	35446
@NP	excitability at the different locations	35462
@NP	excitability	35462
@NP	the different locations	35478
@NP	animals	35525
@NP	only data gathered from stimulation at the base of the tail	35534
@NP	only data	35534
@NP	stimulation	35558
@NP	the base of the tail	35573
@NP	the base	35573
@NP	the tail	35585
@NP	The lowest sensitivity -LRB- highest target force to trigger a response -RRB-	35609
@NP	The lowest sensitivity	35609
@NP	highest target force to trigger a response	35633
@NP	highest target force	35633
@NP	a response	35665
@NP	untreated rats -LRB- Fig. 5 -RRB-	35690
@NP	untreated rats	35690
@NP	Fig. 5	35706
@NP	the average target force at the tip of the von Frey hairs	35715
@NP	the average target force	35715
@NP	the tip of the von Frey hairs	35743
@NP	the tip	35743
@NP	the von Frey hairs	35754
@NP	0.63 ± 0.1 g.	35777
@NP	0.63 ±	35777
@NP	0.1 g.	35784
@NP	This	35791
@NP	rats with grafts only -LRB- 0.31 ± 0.07 g -RRB- and with grafts and cABC	35829
@NP	rats	35829
@NP	grafts only -LRB- 0.31 ± 0.07 g -RRB-	35839
@NP	grafts only	35839
@NP	grafts	35839
@NP	0.31 ± 0.07 g	35852
@NP	0.31 ±	35852
@NP	0.07 g	35859
@NP	grafts and cABC	35876
@NP	0.33 ±	35893
@NP	0.08 g	35900
@NP	Grafts and cABC	35909
@NP	serotonergic fiber regeneration	35933
@NP	this study	35968
@NP	we	35980
@NP	descending axons from three groups of neurons	35994
@NP	descending axons	35994
@NP	three groups of neurons	36016
@NP	three groups	36016
@NP	neurons	36032
@NP	the hindlimb area of the motor cortex	36041
@NP	the hindlimb area	36041
@NP	the motor cortex	36062
@NP	the medial reticular formation	36080
@NP	the raphe nuclei , which project serotonergic -LRB- 5-HT-positive -RRB- fibers	36116
@NP	the raphe nuclei	36116
@NP	serotonergic -LRB- 5-HT-positive -RRB- fibers	36148
@NP	Serotonergic fibers	36185
@NP	the graft and caudal to it	36226
@NP	the graft and caudal	36226
@NP	it	36250
@NP	the abundance	36279
@NP	highly branched serotonergic fibers	36296
@NP	the caudal spinal cord -LRB- Fig. 6A -RRB-	36335
@NP	the caudal spinal cord	36335
@NP	Fig. 6A	36359
@NP	The quantitative analysis of these fibers	36369
@NP	The quantitative analysis	36369
@NP	these fibers	36398
@NP	the bridge revealed a high variability within the groups	36421
@NP	the bridge	36421
@NP	a high variability	36441
@NP	the groups	36467
@NP	the large SD	36490
@NP	the increase caused by grafting	36504
@NP	the increase	36504
@NP	70.1 ± 12.2 , SEM	36557
@NP	70.1 ± 12.2	36557
@NP	SEM	36570
@NP	the rats with grafts only	36577
@NP	the rats	36577
@NP	grafts only	36591
@NP	This increase	36605
@NP	the application of cABC -LRB- 94 ± 14.5 -RRB-	36643
@NP	the application	36643
@NP	cABC -LRB- 94 ± 14.5 -RRB-	36662
@NP	cABC	36662
@NP	94 ± 14.5	36668
@NP	94 ±	36668
@NP	14.5	36673
@NP	the untreated animals -LRB- 15.5 ± 2.2 -RRB- -LRB- Fig. 6B -RRB-	36732
@NP	the untreated animals -LRB- 15.5 ± 2.2 -RRB-	36732
@NP	the untreated animals	36732
@NP	15.5 ± 2.2	36755
@NP	15.5 ±	36755
@NP	2.2	36762
@NP	Fig. 6B	36768
@NP	serotonin in the lumbar spinal cord of injured rats	36787
@NP	serotonin	36787
@NP	the lumbar spinal cord of injured rats	36800
@NP	the lumbar spinal cord	36800
@NP	injured rats	36826
@NP	powerful effects on locomotor function -LRB- Ribotta et al. , 1998 , 2000 -RRB-	36843
@NP	powerful effects	36843
@NP	locomotor function -LRB- Ribotta et al. , 1998 , 2000 -RRB-	36863
@NP	locomotor function	36863
@NP	Ribotta	36883
@NP	et al. , 1998 , 2000	36891
@NP	et al.	36891
@NP	1998	36899
@NP	2000	36905
@NP	no correlation between the number of serotonergic fibers	36912
@NP	no correlation	36912
@NP	the number of serotonergic fibers	36935
@NP	the number	36935
@NP	serotonergic fibers	36949
@NP	caudal to the bridge and locomotor recovery	36975
@NP	caudal	36975
@NP	the bridge and locomotor recovery	36985
@NP	our experiment -LRB- Fig. 6C -RRB-	37032
@NP	our experiment	37032
@NP	Fig. 6C	37048
@NP	Detectable	37058
@NP	axons of two descending motor tracts -LRB- CST and RtST -RRB-	37080
@NP	axons	37080
@NP	two descending motor tracts -LRB- CST and RtST -RRB-	37089
@NP	two descending motor tracts	37089
@NP	CST and RtST	37118
@NP	CST	37118
@NP	RtST	37126
@NP	rostral	37146
@NP	the lesion	37157
@NP	Only a few of these traced axons	37169
@NP	Only a few	37169
@NP	these traced axons	37183
@NP	the bridge	37221
@NP	none	37237
@NP	the caudal part of the spinal cord -LRB- data not shown -RRB-	37265
@NP	the caudal part	37265
@NP	the spinal cord -LRB- data not shown -RRB-	37284
@NP	the spinal cord	37284
@NP	data not shown	37301
@NP	data	37301
@NP	axons	37329
@NP	blood	37339
@NP	the bridge Quantification of myelinated axons	37356
@NP	the bridge Quantification	37356
@NP	myelinated axons	37385
@NP	transverse	37437
@NP	1 µm sections obtained from the center of the bridge	37448
@NP	1 µm sections	37448
@NP	the center of the bridge	37476
@NP	the center	37476
@NP	the bridge	37490
@NP	These counts	37502
@NP	fibers	37560
@NP	this approach -LRB- Fig. 7 -RRB-	37599
@NP	this approach	37599
@NP	Fig. 7	37614
@NP	The lowest count	37623
@NP	the control group	37653
@NP	an average of 1009 ± 237 -LRB- SEM -RRB- myelinated axons	37676
@NP	an average	37676
@NP	1009 ± 237 -LRB- SEM -RRB- myelinated axons	37690
@NP	SEM	37702
@NP	the group with grafts , the average number was -LRB- 1949 ± 486 -RRB-	37728
@NP	the group	37728
@NP	grafts , the average number was	37743
@NP	grafts	37743
@NP	the average number was	37751
@NP	the average number	37751
@NP	1949 ± 486	37775
@NP	1949 ±	37775
@NP	486	37780
@NP	which	37786
@NP	The cABC group	37825
@NP	significantly higher numbers of myelinated axons	37850
@NP	significantly higher numbers	37850
@NP	myelinated axons	37882
@NP	the control group -LRB- 3058 ± 600 -RRB- -LRB- Fig. 8A -RRB-	37918
@NP	the control group -LRB- 3058 ± 600 -RRB-	37918
@NP	the control group	37918
@NP	3058 ± 600	37937
@NP	3058 ±	37937
@NP	600	37944
@NP	Fig. 8A	37950
@NP	the individual axon counts	37965
@NP	the functional outcomes	38011
@NP	open-field locomotion and forelimb/hindlimb coupling	38036
@NP	a significant correlation -LRB- r = 0.63 -RRB-	38091
@NP	a significant correlation	38091
@NP	r	38118
@NP	0.63	38122
@NP	Fig. 8C	38139
@NP	axonal regeneration through the bridge	38165
@NP	axonal regeneration	38165
@NP	the bridge	38193
@NP	the observed functional recovery	38219
@NP	The number of blood vessels in the bridge	38253
@NP	The number	38253
@NP	blood vessels in the bridge	38267
@NP	blood vessels	38267
@NP	the bridge	38284
@NP	either of the groups -LRB- Fig. 8B -RRB-	38342
@NP	either	38342
@NP	the groups -LRB- Fig. 8B -RRB-	38352
@NP	the groups	38352
@NP	Fig. 8B	38364
@NP	creased vascularization of the graft	38378
@NP	creased vascularization	38378
@NP	the graft	38405
@NP	the viability of the grafted cells within the bridge	38443
@NP	the viability	38443
@NP	the grafted cells within the bridge	38460
@NP	the grafted cells	38460
@NP	the bridge	38485
@NP	support of axonal regeneration	38511
@NP	support	38511
@NP	axonal regeneration	38522
@NP	The average numbers	38543
@NP	blood vessels in the graft for the groups with no treatment	38566
@NP	blood vessels	38566
@NP	the graft for the groups with no treatment	38583
@NP	the graft	38583
@NP	the groups with no treatment	38597
@NP	the groups	38597
@NP	no treatment	38613
@NP	grafts/cABC	38644
@NP	264 ± 43 -LRB- SEM -RRB- , 357 ± 43 , and 414 ± 50	38661
@NP	264 ± 43 -LRB- SEM -RRB-	38661
@NP	264 ±	38661
@NP	43 -LRB- SEM -RRB-	38667
@NP	357 ± 43	38677
@NP	357 ±	38677
@NP	43	38683
@NP	414 ± 50	38691
@NP	414 ±	38691
@NP	50	38697
@NP	Discussion Testing the interaction of established experimental treatments	38716
@NP	Discussion	38716
@NP	the interaction of established experimental treatments	38735
@NP	the interaction	38735
@NP	established experimental treatments	38754
@NP	an important step in developing additive , more efficacious treatments for SCI	38793
@NP	an important step	38793
@NP	additive , more efficacious treatments for SCI	38825
@NP	additive , more efficacious treatments	38825
@NP	SCI	38867
@NP	Our study addresses this need and	38872
@NP	study addresses	38876
@NP	this need	38892
@NP	direction for the refinement of future treatments	38915
@NP	direction	38915
@NP	the refinement of future treatments	38929
@NP	the refinement	38929
@NP	future treatments	38947
@NP	untreated rats	38985
@NP	only the group of animals subjected to cell grafts and cABC treatment	39001
@NP	only the group	39001
@NP	animals subjected to cell grafts and cABC treatment	39019
@NP	animals	39019
@NP	cell grafts and cABC treatment	39040
@NP	cell grafts	39040
@NP	cABC treatment	39056
@NP	statistically significant improvements	39078
@NP	locomotor recovery	39120
@NP	both the BBB score and forelimb/hindlimb coupling measurements	39153
@NP	Recovery	39217
@NP	the endpoint of the study	39245
@NP	the endpoint	39245
@NP	the study	39261
@NP	8 weeks	39275
@NP	the injury	39289
@NP	a time	39301
@NP	axonal regeneration	39358
@NP	the graft	39386
@NP	the caudal stump -LRB- Xu et al. , 1995b , 1997 ; Steward et al. , 2003 -RRB-	39405
@NP	the caudal stump	39405
@NP	Xu et al. , 1995b , 1997 ; Steward et al. , 2003	39423
@NP	Xu	39423
@NP	et al. , 1995b , 1997 ; Steward et al. , 2003	39426
@NP	et al.	39426
@NP	1995b	39434
@NP	1997 ; Steward et al.	39441
@NP	1997	39441
@NP	Steward et al.	39447
@NP	Steward	39447
@NP	et al.	39455
@NP	2003	39463
@NP	It	39470
@NP	the functional benefits of the current treatments	39493
@NP	the functional benefits	39493
@NP	the current treatments	39520
@NP	at least two reasons	39584
@NP	the time course	39613
@NP	recovery	39646
@NP	plateau	39663
@NP	the end of the allotted testing period	39674
@NP	the end	39674
@NP	the allotted testing period	39685
@NP	A longer experimental time course	39714
@NP	the long-term benefits of the combinatory treatment	39790
@NP	the long-term benefits	39790
@NP	the combinatory treatment	39816
@NP	small animal numbers in the groups	39872
@NP	small animal numbers	39872
@NP	the groups	39896
@NP	the possible loss of animals before fiber tracing	39912
@NP	the possible loss	39912
@NP	animals before fiber tracing	39933
@NP	animals	39933
@NP	fiber tracing	39948
@NP	fiber	39948
@NP	the laminectomy of three vertebral segments without artificial stabilization	39990
@NP	the laminectomy	39990
@NP	three vertebral segments without artificial stabilization	40009
@NP	three vertebral segments	40009
@NP	artificial stabilization	40042
@NP	strong lordosis , further hampering locomotor recovery	40079
@NP	strong lordosis	40079
@NP	further hampering locomotor recovery	40096
@NP	further	40096
@NP	locomotor recovery	40114
@NP	The hunched body posture	40134
@NP	the nervous system	40226
@NP	sufficient motor control	40259
@NP	the results	40299
@NP	the grafts consisting of SCs and OEG and the application of cABC	40336
@NP	the grafts	40336
@NP	SCs and OEG and the application of cABC	40361
@NP	SCs and OEG	40361
@NP	SCs	40361
@NP	OEG	40369
@NP	the application of cABC	40377
@NP	the application	40377
@NP	cABC	40396
@NP	additive effects	40406
@NP	Our results	40424
@NP	the beneficial effects of cABC	40465
@NP	the beneficial effects	40465
@NP	cABC	40491
@NP	axonal regeneration	40499
@NP	complete spinal cord	40525
@NP	support previous reports	40562
@NP	cABC application	40596
@NP	salutary effects	40628
@NP	brain injury	40651
@NP	Moon	40665
@NP	et al. , 2001	40670
@NP	et al.	40670
@NP	2001	40678
@NP	incomplete lesions	40688
@NP	the spinal cord -LRB- Bradbury et al. , 2002 ; Yick et al. , 2003 -RRB-	40710
@NP	the spinal cord	40710
@NP	Bradbury	40727
@NP	et al. , 2002 ; Yick et al. , 2003	40736
@NP	et al.	40736
@NP	2002 ; Yick et al.	40744
@NP	2002	40744
@NP	Yick et al.	40750
@NP	Yick	40750
@NP	et al.	40755
@NP	2003	40763
@NP	The application of cABC	40770
@NP	The application	40770
@NP	cABC	40789
@NP	conjunction	40836
@NP	grafted tissue	40853
@NP	scar tissue at the graft-host interface	40877
@NP	scar tissue	40877
@NP	the graft-host interface	40892
@NP	a barrier for axons	40928
@NP	a barrier	40928
@NP	axons	40942
@NP	the graft -LRB- Chau et al. , 2004 -RRB-	40973
@NP	the graft	40973
@NP	Chau	40984
@NP	et al. , 2004	40989
@NP	et al.	40989
@NP	2004	40997
@NP	It	41004
@NP	one control animal	41026
@NP	a BBB score of 6	41053
@NP	a BBB score	41053
@NP	6	41068
@NP	its recovery	41074
@NP	the treated group	41113
@NP	This recovery	41132
@NP	the surgery	41170
@NP	any chance of axonal sparing	41193
@NP	any chance	41193
@NP	axonal sparing	41207
@NP	Even a relesion	41223
@NP	9 weeks	41239
@NP	hindlimb activity	41270
@NP	This phenomenon	41289
@NP	the plastic capabilities of the spinal networks controlling locomotion	41317
@NP	the plastic capabilities	41317
@NP	the spinal networks controlling locomotion	41345
@NP	the spinal networks	41345
@NP	locomotion	41377
@NP	review	41393
@NP	Pearson , 2000 ; Edgerton et al. , 2001 ; Rossignol et al. , 2002	41405
@NP	Pearson , 2000 ; Edgerton et al. , 2001 ; Rossignol et al.	41405
@NP	Pearson , 2000	41405
@NP	Pearson	41405
@NP	2000	41414
@NP	Edgerton et al. , 2001	41420
@NP	Edgerton	41420
@NP	et al. , 2001	41429
@NP	et al.	41429
@NP	2001	41437
@NP	Rossignol et al.	41443
@NP	Rossignol	41443
@NP	et al.	41453
@NP	2002	41461
@NP	Another unexpected result	41468
@NP	the considerable number of myelinated axons	41498
@NP	the considerable number	41498
@NP	myelinated axons	41525
@NP	serotonergic axons observed in Matrigelonly grafts	41546
@NP	serotonergic axons	41546
@NP	Matrigelonly grafts	41577
@NP	these fibers	41598
@NP	Matrigel-only bridges in previous studies -LRB- Xu et al. , 1997 -RRB-	41629
@NP	Matrigel-only bridges	41629
@NP	previous studies -LRB- Xu et al. , 1997 -RRB-	41654
@NP	previous studies	41654
@NP	Xu	41672
@NP	et al. , 1997	41675
@NP	et al.	41675
@NP	1997	41683
@NP	This	41690
@NP	the finding	41699
@NP	none of the animals	41719
@NP	none	41719
@NP	the animals	41727
@NP	the spinal cord pulled out of the channel	41743
@NP	the spinal cord	41743
@NP	the channel	41773
@NP	the new technique for implanting an SC bridge used in this study	41808
@NP	the new technique	41808
@NP	an SC bridge used in this study	41841
@NP	an SC bridge	41841
@NP	this study	41862
@NP	the channel	41884
@NP	the SCs	41915
@NP	fluid Matrigel	41926
@NP	windows on the dorsal surface of the channel	41949
@NP	windows	41949
@NP	the dorsal surface of the channel	41960
@NP	the dorsal surface	41960
@NP	the channel	41982
@NP	better apposition	42006
@NP	the SCs and the spinal cord stumps	42032
@NP	the SCs	42032
@NP	the spinal cord stumps	42044
@NP	It	42068
@NP	HRP-labeled CST axons	42094
@NP	a graft of collagen	42122
@NP	a graft	42122
@NP	collagen	42133
@NP	the collagen	42147
@NP	fluid form	42177
@NP	the matrix	42237
@NP	the collagen	42253
@NP	solid gel form -LRB- Joosten et al. , 1995 -RRB-	42282
@NP	solid gel form	42282
@NP	Joosten	42298
@NP	et al. , 1995	42306
@NP	et al.	42306
@NP	1995	42314
@NP	This study	42321
@NP	the	42357
@NP	fluid form	42375
@NP	it	42387
@NP	the surface of the cord stump	42412
@NP	the surface	42412
@NP	the cord stump	42427
@NP	A major question after experimental treatments to repair the injured spinal cord	42443
@NP	A major question	42443
@NP	experimental treatments	42466
@NP	the injured spinal cord	42500
@NP	functional recovery	42544
@NP	regenerated fibers	42577
@NP	appropriate targets	42612
@NP	the lesion or changes	42638
@NP	the lesion	42638
@NP	changes	42652
@NP	existing circuitries	42663
@NP	the lesion	42700
@NP	review	42716
@NP	Fouad and Pearson , 2004	42728
@NP	Fouad and Pearson	42728
@NP	2004	42747
@NP	some studies	42762
@NP	axonal regeneration and functional recovery	42789
@NP	regeneration	42796
@NP	complete SCI	42839
@NP	treatment -LRB- Cheng et al. , 1996 ; Ramo ' n-Cueto et al. , 2000 -RRB-	42863
@NP	treatment	42863
@NP	Cheng	42874
@NP	et al. , 1996 ; Ramo ' n-Cueto et al. , 2000	42880
@NP	et al.	42880
@NP	1996 ; Ramo ' n-Cueto et al.	42888
@NP	1996	42888
@NP	Ramo ' n-Cueto et al.	42894
@NP	Ramo ' n-Cueto	42894
@NP	Ramo '	42894
@NP	et al.	42908
@NP	2000	42916
@NP	very few	42923
@NP	evidence of reconnection	42946
@NP	evidence	42946
@NP	reconnection	42958
@NP	One link between regeneration and functional recovery	42972
@NP	One link	42972
@NP	regeneration and functional recovery	42989
@NP	histological evidence	43029
@NP	fibers growing through the graft and into the caudal stump of the spinal cord	43054
@NP	fibers	43054
@NP	the graft	43077
@NP	the caudal stump of the spinal cord	43096
@NP	the caudal stump	43096
@NP	the spinal cord	43116
@NP	Traced fibers of the CST and the RtST	43133
@NP	Traced fibers	43133
@NP	the CST and the RtST	43150
@NP	the CST	43150
@NP	the RtST	43162
@NP	the SC bridge	43191
@NP	none	43210
@NP	the bridge	43253
@NP	the contiguous caudal cord	43269
@NP	contrast	43300
@NP	rats with grafted cells in our study	43313
@NP	rats	43313
@NP	grafted cells in our study	43323
@NP	grafted cells	43323
@NP	our study	43340
@NP	5-HT fibers that grew through the bridge and projected into the caudal stump	43351
@NP	5-HT fibers	43351
@NP	the bridge	43381
@NP	the caudal stump	43411
@NP	abundance	43442
@NP	This	43453
@NP	previous experiments	43467
@NP	SC bridges combined with OEG grafts	43497
@NP	SC bridges	43497
@NP	OEG grafts	43522
@NP	the presence of 5-HT fibers	43540
@NP	the presence	43540
@NP	5-HT fibers	43556
@NP	the bridge	43578
@NP	a complete transection gap -LRB- Ramo ' n-Cueto et al. , 1998 -RRB-	43599
@NP	a complete transection gap	43599
@NP	Ramo ' n-Cueto et al. , 1998	43627
@NP	Ramo ' n-Cueto et al.	43627
@NP	Ramo ' n-Cueto	43627
@NP	Ramo '	43627
@NP	1998	43649
@NP	the application of serotonin	43664
@NP	the application	43664
@NP	serotonin	43683
@NP	the grafting of serotonin-secreting cells to the caudal spinal cord	43696
@NP	the grafting	43696
@NP	serotonin-secreting cells to the caudal spinal cord	43712
@NP	serotonin-secreting cells	43712
@NP	the caudal spinal cord	43741
@NP	significant locomotor recovery	43788
@NP	Ribotta	43820
@NP	et al. , 2000 ; Antri et al. , 2002	43828
@NP	et al.	43828
@NP	2000 ; Antri et al.	43836
@NP	2000	43836
@NP	Antri et al.	43842
@NP	Antri	43842
@NP	et al.	43848
@NP	2002	43856
@NP	it	43863
@NP	no correlation	43894
@NP	an increased number of serotonergic fibers and locomotor recovery	43917
@NP	an increased number	43917
@NP	serotonergic fibers and locomotor recovery	43940
@NP	serotonergic fibers	43940
@NP	locomotor recovery	43964
@NP	Possible explanations	43994
@NP	greater numbers of regenerating serotonergic fibers	44035
@NP	greater numbers	44035
@NP	serotonergic fibers	44067
@NP	locomotor recovery	44112
@NP	they	44132
@NP	the lumbar cord	44166
@NP	the fibers	44186
@NP	The significant correlation	44218
@NP	we	44251
@NP	functional recovery and the number of myelinated axons	44268
@NP	functional recovery	44268
@NP	the number of myelinated axons	44292
@NP	the number	44292
@NP	myelinated axons	44306
@NP	the center of the bridge	44326
@NP	the center	44326
@NP	the bridge	44340
@NP	fibers other than CST , RtST , or serotonergic axons	44365
@NP	fibers	44365
@NP	CST , RtST , or serotonergic axons	44383
@NP	CST	44383
@NP	RtST	44388
@NP	serotonergic axons	44397
@NP	the observed recovery	44433
@NP	Plausible candidates	44456
@NP	axons	44481
@NP	propriospinal interneurons	44490
@NP	SC bridges	44548
@NP	Xu	44560
@NP	et al. , 1995b , 1997	44563
@NP	et al.	44563
@NP	1995b	44571
@NP	1997	44578
@NP	the interneurons	44585
@NP	relays for lesioned axons	44617
@NP	relays	44617
@NP	lesioned axons	44628
@NP	rostral	44653
@NP	a lesion	44664
@NP	Fouad	44674
@NP	et al. , 2001	44680
@NP	et al.	44680
@NP	2001	44688
@NP	Raineteau and Schwab , 2001	44694
@NP	Raineteau and Schwab	44694
@NP	2001	44716
@NP	Raineteau et al. , 2001	44722
@NP	Raineteau	44722
@NP	et al. , 2001	44732
@NP	et al.	44732
@NP	2001	44740
@NP	Bareyre et al. , 2004	44746
@NP	Bareyre	44746
@NP	et al. , 2004	44754
@NP	et al.	44754
@NP	2004	44762
@NP	Propriospinal interneurons	44769
@NP	the present study	44815
@NP	retrograde tracers	44863
@NP	future work	44885
@NP	the relationship between regeneration and functional recovery	44933
@NP	the relationship	44933
@NP	regeneration and functional recovery	44958
@NP	a relesion of the spinal cord	44996
@NP	a relesion	44996
@NP	the spinal cord	45010
@NP	one rat	45049
@NP	it	45066
@NP	the anterograde tracing used in our study	45096
@NP	the anterograde	45096
@NP	our study	45128
@NP	A finding supporting a reestablished connection via the lesion site	45139
@NP	A finding	45139
@NP	a reestablished connection via the lesion site	45160
@NP	a	45160
@NP	connection via the lesion site	45176
@NP	connection	45176
@NP	the lesion site	45191
@NP	behavioral testing on a slippery surface	45218
@NP	behavioral testing	45218
@NP	a slippery surface	45240
@NP	`` stationary '' forelimb stepping	45267
@NP	`` stationary '' forelimb	45267
@NP	sensory feedback to the hindlimbs	45299
@NP	sensory feedback	45299
@NP	the hindlimbs	45319
@NP	a minimum	45348
@NP	no sliding over the surface	45367
@NP	no sliding	45367
@NP	the surface	45383
@NP	these circumstances	45411
@NP	the hindlimbs of a few rats with high locomotor scores	45432
@NP	the hindlimbs	45432
@NP	a few rats with high locomotor scores	45449
@NP	a few rats	45449
@NP	high locomotor scores	45465
@NP	the forelimbs	45523
@NP	both	45554
@NP	descending input	45607
@NP	Promoting axonal regeneration in the injured spinal cord	45625
@NP	Promoting axonal regeneration	45625
@NP	the injured spinal cord	45658
@NP	descending motor axons	45704
@NP	Sprouting and growth of sensory fibers	45728
@NP	Sprouting and growth	45728
@NP	sensory fibers	45752
@NP	our study	45799
@NP	sensory fibers	45838
@NP	we	45854
@NP	responses to tactile cutaneous stimuli in dermatomes	45866
@NP	responses	45866
@NP	tactile cutaneous stimuli in dermatomes	45879
@NP	tactile cutaneous stimuli	45879
@NP	dermatomes	45908
@NP	the lesion	45929
@NP	The finding that treated rats	45941
@NP	The finding	45941
@NP	rats	45966
@NP	significantly increased sensitivity	45981
@NP	tactile stimuli	46020
@NP	the clinical value of regeneration	46044
@NP	the clinical value	46044
@NP	regeneration	46066
@NP	treatments	46090
@NP	increased pain	46110
@NP	a treatment	46131
@NP	our results	46174
@NP	increased pain or allodynia	46231
@NP	rats	46270
@NP	signs	46282
@NP	spasticity in human patients	46304
@NP	spasticity	46304
@NP	human patients	46318
@NP	the increased responses to tactile stimuli	46343
@NP	the increased responses	46343
@NP	tactile stimuli	46370
@NP	a sign	46402
@NP	increased spasticity	46412
@NP	disinhibition of spinal pathways -LRB- Calancie et al. , 1993 -RRB-	46446
@NP	disinhibition	46446
@NP	spinal pathways -LRB- Calancie et al. , 1993 -RRB-	46463
@NP	spinal pathways	46463
@NP	Calancie	46480
@NP	et al. , 1993	46489
@NP	et al.	46489
@NP	1993	46497
@NP	changes	46506
@NP	neuronal properties -LRB- Bennett et al. , 2004 ; Li et al. , 2004 -RRB-	46517
@NP	neuronal properties	46517
@NP	Bennett	46538
@NP	et al. , 2004 ; Li et al. , 2004	46546
@NP	et al.	46546
@NP	2004 ; Li et al.	46554
@NP	2004	46554
@NP	Li et al.	46560
@NP	Li	46560
@NP	et al.	46563
@NP	2004	46571
@NP	Increased sensory feedback	46578
@NP	locomotor recovery	46638
@NP	SCI -LRB- Pearson , 2001 -RRB-	46663
@NP	SCI	46663
@NP	Pearson	46668
@NP	2001	46677
@NP	Changes in sensitivity as reported above	46684
@NP	Changes	46684
@NP	sensitivity as reported above	46695
@NP	sensitivity	46695
@NP	movements	46757
@NP	a rough surface	46783
@NP	greater levels of cutaneous feedback	46810
@NP	greater levels	46810
@NP	cutaneous feedback	46828
@NP	this	46857
@NP	the case	46870
@NP	it	46888
@NP	changes in ground	46904
@NP	changes	46904
@NP	ground	46915
@NP	a walking sequence initiate reflex-like stepping	46937
@NP	a walking sequence initiate reflex-like	46937
@NP	The implications of the current study	46987
@NP	The implications	46987
@NP	the current study	47007
@NP	an important	47030
@NP	stone	47052
@NP	the development of a combined treatment for SCI	47065
@NP	the development	47065
@NP	a combined treatment for SCI	47084
@NP	a combined treatment	47084
@NP	SCI	47109
@NP	References	47921
@NP	Aebischer	47932
@NP	P	47942
@NP	Guenard V	47945
@NP	Winn SR	47956
@NP	Valentini RF	47965
@NP	Galletti PM -LRB- 1988 -RRB- Blindended semipermeable guidance channels	47979
@NP	Galletti PM	47979
@NP	1988	47992
@NP	Blindended semipermeable guidance channels	47998
@NP	peripheral nerve regeneration in the absence of a distal nerve stump	48049
@NP	peripheral nerve regeneration	48049
@NP	the absence of a distal nerve stump	48082
@NP	the absence	48082
@NP	a distal nerve stump	48097
@VP	Promotes	90
@VP	exist	772
@VP	has to overcome these obstacles	904
@VP	to overcome these obstacles	908
@VP	overcome these obstacles	911
@VP	provide a growth-supportive substrate for axonal regeneration	1176
@VP	-RSB-	1258
@VP	-LRB- 3 -RRB- to enable regenerated axons	1265
@VP	to enable regenerated axons	1269
@VP	to re-enter the spinal cord -LRB- olfactory ensheathing glia -RRB-	1316
@VP	re-enter the spinal cord -LRB- olfactory ensheathing glia -RRB-	1319
@VP	provided significant benefit compared with grafts only or the untreated group	1455
@VP	grew through the bridge and into the caudal spinal cord	1773
@VP	did not successfully regenerate through the bridge	1919
@VP	regenerate through the bridge	1940
@VP	were the driving force for the observed recovery	2028
@VP	was a significant correlation between numbers of myelinated fibers in the bridge	2084
@VP	improved coupling of forelimb and hindlimb as well as open-field locomotion	2169
@VP	see Schwab and Bartholdi , 1996	2648
@VP	to prevent ongoing tissue damage and promote regrowth and reconnection of axons	2754
@VP	prevent ongoing tissue damage and promote regrowth and reconnection of axons	2757
@VP	prevent ongoing tissue damage	2757
@VP	promote regrowth and reconnection of axons	2791
@VP	targeting these processes	4073
@VP	facilitating regeneration and functional recovery after SCI	4139
@VP	illustrating the need to overcome multiple factors that limit axon growth	4284
@VP	to overcome multiple factors that limit axon growth	4306
@VP	overcome multiple factors that limit axon growth	4309
@VP	limit axon growth	4340
@VP	may bring about increased axonal growth and functional recovery	4421
@VP	bring about increased axonal growth and functional recovery	4425
@VP	searching for the optimal combination strategy for SCI repair	4489
@VP	have demonstrated the additive potential of two or more therapeutic approaches	4572
@VP	demonstrated the additive potential of two or more therapeutic approaches	4577
@VP	have also been tested -LRB- Guth et al. , 1994 ; Mu et al. , 2000 -RRB-	5062
@VP	been tested -LRB- Guth et al. , 1994 ; Mu et al. , 2000 -RRB-	5072
@VP	tested -LRB- Guth et al. , 1994 ; Mu et al. , 2000 -RRB-	5077
@VP	regard to Schwann cell -LRB- SC -RRB- implants specifically	5127
@VP	to Schwann cell -LRB- SC -RRB- implants specifically	5134
@VP	improved axonal regeneration	5448
@VP	reducing inhibitory cues of the scar tissue -LRB- chondroitinase ABC -RRB-	5538
@VP	described previously	5938
@VP	cut into small pieces	5997
@VP	enzymatically dissociated	6192
@VP	supplemented with three	6252
@VP	described previously	6457
@VP	assessed by using the S100 and Hoechst stains	6522
@VP	using the S100 and Hoechst stains	6534
@VP	was 95 -- 98 %	6568
@VP	purified cultures of OEG	6615
@VP	were prepared from the nerve fiber	6640
@VP	prepared from the nerve fiber	6645
@VP	modified from one described previously -LRB- Ramo ' n-Cueto et al. , 1998 -RRB-	6759
@VP	described previously -LRB- Ramo ' n-Cueto et al. , 1998 -RRB-	6777
@VP	was removed	6836
@VP	removed	6840
@VP	was taken to minimize the inclusion of non-nerve fiber layer bulb tissue	6857
@VP	taken to minimize the inclusion of non-nerve fiber layer bulb tissue	6861
@VP	to minimize the inclusion of non-nerve fiber layer bulb tissue	6867
@VP	minimize the inclusion of non-nerve fiber layer bulb tissue	6870
@VP	dissociated	6940
@VP	described previously	7151
@VP	preceded harvesting at confluency for transplantation	7311
@VP	harvesting at confluency for transplantation	7320
@VP	Checking the purity	7366
@VP	was used with Hoechst nuclear staining	7440
@VP	used with Hoechst nuclear staining	7444
@VP	was found to be between 94 and 98 %	7487
@VP	found to be between 94 and 98 %	7491
@VP	to be between 94 and 98 %	7497
@VP	be between 94 and 98 %	7500
@VP	Cultured SCs or OEG	7562
@VP	were harvested in DMEM/F -12 medium	7582
@VP	harvested in DMEM/F -12 medium	7587
@VP	were trypsinized to remove them from the dishes	7646
@VP	trypsinized to remove them from the dishes	7651
@VP	to remove them from the dishes	7663
@VP	remove them from the dishes	7666
@VP	were counted using a hemocytometer	7709
@VP	counted using a hemocytometer	7714
@VP	using a hemocytometer	7722
@VP	grafting	7864
@VP	received a total of 5 x 106 SCs for transplantation	7886
@VP	containing 4 x 105 cells immediately before spinal cord injection	8000
@VP	were kept at a 12 h light/dark cycle	8217
@VP	kept at a 12 h light/dark cycle	8222
@VP	ensured that regeneration of axons could be identified definitively	8316
@VP	could be identified definitively	8351
@VP	be identified definitively	8357
@VP	identified definitively	8360
@VP	was approved by the animal welfare committee at the University of Alberta	8400
@VP	approved by the animal welfare committee at the University of Alberta	8404
@VP	handled for 2 weeks	8504
@VP	are illustrated in Fig. 1	9153
@VP	illustrated in Fig. 1	9157
@VP	is not reported here	9279
@VP	reported here	9286
@VP	grafting Animals	9342
@VP	was applied to protect the eyes from dehydration	9685
@VP	applied to protect the eyes from dehydration	9689
@VP	to protect the eyes from dehydration	9697
@VP	protect the eyes from dehydration	9700
@VP	were severed along with the dura mater	9811
@VP	severed along with the dura mater	9816
@VP	was completely transected	9867
@VP	completely transected	9871
@VP	encompassing T8	9926
@VP	was removed	9942
@VP	removed	9946
@VP	lifted after removal of the spinal cord segment to ensure complete discontinuity	9990
@VP	to ensure complete discontinuity	10038
@VP	ensure complete discontinuity	10041
@VP	were removed	10115
@VP	removed	10120
@VP	was stopped using Gelfoam -LRB- Upjohn , Kalamazoo , MI -RRB-	10142
@VP	stopped using Gelfoam -LRB- Upjohn , Kalamazoo , MI -RRB-	10146
@VP	using Gelfoam -LRB- Upjohn , Kalamazoo , MI -RRB-	10154
@VP	were drawn into a glass pipette with a tip diameter of 150	10218
@VP	drawn into a glass pipette with a tip diameter of 150	10223
@VP	attached to a micromanipulator	10342
@VP	containing ≈ 105 OEG in DMEM/F -12	10568
@VP	was grafted into each site	10601
@VP	grafted into each site	10605
@VP	provided by T.	10831
@VP	previously cleaned	10890
@VP	drawn back 1 mm to permit the insertion of the caudal stump 1mminto the channel	10971
@VP	to permit the insertion of the caudal stump 1mminto the channel	10987
@VP	permit the insertion of the caudal stump 1mminto the channel	10990
@VP	1mminto the channel	11031
@VP	had been crafted into the dorsal surface of the channel before implantation	11083
@VP	been crafted into the dorsal surface of the channel before implantation	11087
@VP	crafted into the dorsal surface of the channel before implantation	11092
@VP	to slowly fill the channel	11238
@VP	slowly fill the channel	11241
@VP	were then closed and sealed with Matrigel	11278
@VP	closed and sealed with Matrigel	11288
@VP	halted for 5 min to allow semisolidification of the Matrigel-SC cable at 37 °C	11337
@VP	to allow semisolidification of the Matrigel-SC cable at 37 °C	11354
@VP	allow semisolidification of the Matrigel-SC cable at 37 °C	11357
@VP	using pumps	11449
@VP	see below	11462
@VP	was rinsed with chondroitinase or vehicle	11520
@VP	rinsed with chondroitinase or vehicle	11524
@VP	was blinded for both kinds of treatments	11575
@VP	blinded for both kinds of treatments	11579
@VP	provide deliv	11825
@VP	was fixed with sutures to the caudal musculature	12089
@VP	fixed with sutures to the caudal musculature	12093
@VP	were performed every other day for 4 weeks under short isoflurane anesthesia	12297
@VP	performed every other day for 4 weeks under short isoflurane anesthesia	12302
@VP	were placed into skin pouches on the back of the rats	12381
@VP	placed into skin pouches on the back of the rats	12386
@VP	kept in position with sutures	12439
@VP	were sutured in layers	12501
@VP	sutured in layers	12506
@VP	was closed with wound clips	12538
@VP	closed with wound clips	12542
@VP	contained antibody -LRB- IgG -RRB- at a concentration of 3 mg/ml in PBS	12848
@VP	was 0.6 µl/h -LRB- ≈ 1.8 µg/h -RRB-	12946
@VP	were kept on a thermostatically regulated heating pad until completely awake	12999
@VP	kept on a thermostatically regulated heating pad until completely awake	13004
@VP	showed signs of dehydration	13353
@VP	was administered once each day for 4 d starting at 1 d before surgery	13461
@VP	administered once each day for 4 d starting at 1 d before surgery	13465
@VP	was reestablished	13616
@VP	reestablished	13620
@VP	was fed to each rat twice each day	13705
@VP	fed to each rat twice each day	13709
@VP	were exchanged under isoflurane anesthesia	13762
@VP	exchanged under isoflurane anesthesia	13767
@VP	were removed	13842
@VP	removed	13847
@VP	degraded chondroitin sulfate at the host cord/SC graft interface	13923
@VP	recognize either intact or digested chondroitin sulfate	14022
@VP	recognizes an epitope created after cABC degradation of chondroitin-4 sulfate	14279
@VP	created after cABC degradation of chondroitin-4 sulfate	14301
@VP	does not identify the intact form -LRB- Moon et al. , 2001 -RRB-	14361
@VP	identify the intact form -LRB- Moon et al. , 2001 -RRB-	14370
@VP	used	14437
@VP	were CS-56 -LRB- 1:500 ; Sigma-Aldrich , St.	14442
@VP	recognizes an epitope	14498
@VP	recognizes the CSPG core protein of neurocan -LRB- Moon et al. , 2002 -RRB-	14688
@VP	would indicate cABC efficacy	14860
@VP	indicate cABC efficacy	14866
@VP	drawn through the center of the cord	15363
@VP	were evaluated	15400
@VP	evaluated	15405
@VP	indicating greater staining	15474
@VP	averaging measured intensity values across all sections examined	15574
@VP	measured intensity values across all sections examined	15584
@VP	examined	15630
@VP	stepping movements	15688
@VP	score	15926
@VP	was determined by two blinded observers	15985
@VP	determined by two blinded observers	15989
@VP	accompanies hindlimb activity	16113
@VP	were observed for 4 min	16239
@VP	observed for 4 min	16244
@VP	were disregarded	16328
@VP	disregarded	16333
@VP	are taken into account	16756
@VP	taken into account	16760
@VP	To quantify forelimb	16780
@VP	quantify forelimb	16783
@VP	made by an ipsilateral forelimb / hindlimb pair was recorded	16840
@VP	was recorded	16887
@VP	recorded	16891
@VP	determined by dividing the number of correct couplings	16954
@VP	dividing the number of correct couplings	16968
@VP	was followed by a hindlimb step , or vice versa	17035
@VP	followed by a hindlimb step , or vice versa	17039
@VP	were chosen	17271
@VP	chosen	17276
@VP	is to resolve whether hindlimb movements	17377
@VP	to resolve whether hindlimb movements	17380
@VP	resolve whether hindlimb movements	17383
@VP	sliding over the ground	17504
@VP	To investigate this question	17529
@VP	investigate this question	17532
@VP	tested open-field locomotion on different surfaces	17562
@VP	described above	17676
@VP	used a slippery surface and a rough surface	17696
@VP	are new and have not been described in the literature	17753
@VP	are new	17753
@VP	have not been described in the literature	17765
@VP	been described in the literature	17774
@VP	described in the literature	17779
@VP	To test locomotion on a slippery surface	17808
@VP	test locomotion on a slippery surface	17811
@VP	covered by a thin layer of paraffin oil	17938
@VP	performed stepping movements with their forelimbs	18061
@VP	stepping movements with their forelimbs	18071
@VP	sliding	18184
@VP	was limited	18192
@VP	limited	18196
@VP	occurred in a stepping sequence	18250
@VP	were scored	18282
@VP	scored	18287
@VP	To test the influence of increased sensory feedback	18405
@VP	test the influence of increased sensory feedback	18408
@VP	were placed on a rough carpet	18467
@VP	placed on a rough carpet	18472
@VP	were analyzed as described during open-field locomotion	18534
@VP	analyzed as described during open-field locomotion	18539
@VP	described during open-field locomotion	18551
@VP	was also performed at 9 weeks after transection	18601
@VP	performed at 9 weeks after transection	18610
@VP	were tested on the carpet	18662
@VP	tested on the carpet	18667
@VP	was wrapped in a towel and held such that its covered head could move freely	18714
@VP	was wrapped in a towel	18714
@VP	wrapped in a towel	18718
@VP	held such that its covered head could move freely	18741
@VP	could move freely	18773
@VP	move freely	18779
@VP	remained exposed	18810
@VP	were used to handling and restraining	18845
@VP	used to handling and restraining	18850
@VP	handling and restraining	18858
@VP	remained calm	18889
@VP	lost their ascending projections	18952
@VP	stimulated with a set of von Frey hairs -LRB- Stoelting , Wood Dale , IL -RRB-	19096
@VP	applied -LRB- target force , 0.04 -- 1 g -RRB-	19218
@VP	would slightly bend and then be directly removed	19263
@VP	bend and then be directly removed	19278
@VP	bend	19278
@VP	be directly removed	19292
@VP	was repeated three times	19405
@VP	repeated three times	19409
@VP	twitch response was observed	19437
@VP	was observed	19453
@VP	observed	19457
@VP	was used	19489
@VP	used	19493
@VP	to produce a response	19532
@VP	produce a response	19535
@VP	was repeated three times before the sensation threshold was recorded	19554
@VP	repeated three times before the sensation threshold was recorded	19558
@VP	was recorded	19610
@VP	recorded	19614
@VP	were separated by at least 2 min to avoid desensitization	19664
@VP	separated by at least 2 min to avoid desensitization	19669
@VP	to avoid desensitization	19697
@VP	avoid desensitization	19700
@VP	traced under Hypnorm/Midazolam anesthesia -LRB- as described above -RRB-	19851
@VP	described above	19897
@VP	tracing	19927
@VP	using a Hamilton syringe as described previously	20123
@VP	described previously	20151
@VP	tracing of the RtST	20198
@VP	was stereotaxically guided into the giant nucleus of the reticular formation	20286
@VP	guided into the giant nucleus of the reticular formation	20306
@VP	coordinates from Paxinos and Watson , 1986	20364
@VP	was slowly injected over a period of 5 min	20513
@VP	injected over a period of 5 min	20524
@VP	were removed and postfixed overnight in the same fixative at 4 °C	20814
@VP	removed and postfixed overnight in the same fixative at 4 °C	20819
@VP	photographed	20992
@VP	taken from the middle of the SC bridge	21040
@VP	was then further fixed in 1 % buffered osmium tetroxide for 2	21209
@VP	fixed in 1 %	21226
@VP	buffered osmium tetroxide for 2	21238
@VP	dehydrated	21276
@VP	cut transversely in semithin sections -LRB- 1 µm -RRB-	21371
@VP	to analyze SC bridge histology	21514
@VP	analyze SC bridge histology	21517
@VP	to determine the number of myelinated axons and blood vessels therein	21549
@VP	determine the number of myelinated axons and blood vessels therein	21552
@VP	frozen in Tissue-Tek OCT compound	21773
@VP	cut into 30-µm-thick sagittal sections	21843
@VP	was evaluated in cervical cord sections	21907
@VP	evaluated in cervical cord sections	21911
@VP	were counted as described previously -LRB- Xu et al. , 1995b -RRB-	22000
@VP	counted as described previously -LRB- Xu et al. , 1995b -RRB-	22005
@VP	described previously -LRB- Xu et al. , 1995b -RRB-	22016
@VP	stained	22069
@VP	was outlined	22219
@VP	outlined	22223
@VP	was counted	22455
@VP	counted	22459
@VP	chosen for evaluation	22502
@VP	then washed in 0.1 M PB three times	22650
@VP	followed by two washing cycles in PB for 10 min	22777
@VP	washing cycles in PB for 10 min	22793
@VP	was performed with 0.4 % NaBH4 for 10 min	22835
@VP	performed with 0.4 % NaBH4 for 10 min	22839
@VP	washing the slides in PB three times for 20 min	22883
@VP	were incubated with 0.1 M citrate buffer , pH 4.5 , overnight at 4 °C	22937
@VP	incubated with 0.1 M citrate buffer , pH 4.5 , overnight at 4 °C	22942
@VP	warmed to room temperature	23035
@VP	microwaved for 1 min at 600 W , followed by two cycles of 30 s at 600	23066
@VP	followed by two cycles of 30 s at 600	23097
@VP	were left to cool for 30 min	23196
@VP	left to cool for 30 min	23201
@VP	to cool for 30 min	23206
@VP	cool for 30 min	23209
@VP	were subsequently blocked in 1 %	23229
@VP	subsequently blocked in 1 %	23234
@VP	-RSB-	23402
@VP	added in a dilution of 1:8000 containing 4 % normal goat serum -LRB- NGS -RRB-	23454
@VP	containing 4 % normal goat serum -LRB- NGS -RRB-	23484
@VP	left on the slides overnight at 4 °C	23526
@VP	was added and left for 45 min at room temperature	23697
@VP	added and left for 45 min at room temperature	23701
@VP	were then rinsed twice in PBS for 10 min	23755
@VP	was added for 45 min	23823
@VP	added for 45 min	23827
@VP	washing steps of 10 min each in PBS	23857
@VP	were preincubated with 0.05 M Tris , pH 8.0 , for 5 min	23899
@VP	preincubated with 0.05 M Tris , pH 8.0 , for 5 min	23904
@VP	were dried overnight and coverslipped	24163
@VP	dried overnight and coverslipped	24168
@VP	counts The number of 5-HT-positive fibers caudal to the lesion site	24213
@VP	caudal to the lesion site	24255
@VP	alternating 25 µm	24407
@VP	were cut to visualize CST and RtST fibers	24443
@VP	cut to visualize CST and RtST fibers	24448
@VP	to visualize CST and RtST fibers	24452
@VP	visualize CST and RtST fibers	24455
@VP	chosen for the analysis of 5-HT-positive fibers	24522
@VP	were separated by 75 µm intervals	24570
@VP	separated by 75 µm intervals	24575
@VP	minimized the possibility of counting the same fiber twice	24610
@VP	counting the same fiber twice	24639
@VP	were counted	24809
@VP	counted	24814
@VP	first observed under a fluorescent microscope to detect labeling with Micro Ruby	24885
@VP	to detect labeling with Micro Ruby	24931
@VP	detect labeling with Micro Ruby	24934
@VP	were detected rostral to the lesions and , in some cases , in the bridge	24990
@VP	detected rostral to the lesions and , in some cases , in the bridge	24995
@VP	described previously	25293
@VP	was performed	25486
@VP	performed	25490
@VP	had pulled out of the channel	25685
@VP	pulled out of the channel	25689
@VP	was larger than 50 % of the spinal cord	25796
@VP	were performed using GraphPad Prism	25860
@VP	performed using GraphPad Prism	25865
@VP	using GraphPad Prism	25875
@VP	were made using the Mann -- Whitney U test	25938
@VP	made using the Mann -- Whitney U test	25943
@VP	using the Mann -- Whitney U test	25948
@VP	were considered significant	26002
@VP	considered significant	26007
@VP	was considered highly significant	26039
@VP	considered highly significant	26043
@VP	are given as SEM	26081
@VP	given as SEM	26085
@VP	digested -LRB- 2B6 -RRB- chondroitin sulfate	26367
@VP	using the percentage of successful forelimb / hindlimb coupling -LRB- B -RRB-	26551
@VP	start to become apparent at 8 weeks after surgery	26684
@VP	to become apparent at 8 weeks after surgery	26690
@VP	become apparent at 8 weeks after surgery	26693
@VP	represent the scores of single animals	26744
@VP	treated with OEG and Schwann cell grafts as well as with cABC	26840
@VP	are organized in rows from left to right	27015
@VP	organized in rows from left to right	27019
@VP	left to right	27042
@VP	using von Frey hairs at the base of the tail	27084
@VP	shows increased responsiveness in all of the treated groups	27129
@VP	were found to grow into the caudal spinal cord	27234
@VP	found to grow into the caudal spinal cord	27239
@VP	to grow into the caudal spinal cord	27245
@VP	grow into the caudal spinal cord	27248
@VP	is illustrated in B.	27343
@VP	illustrated in B.	27346
@VP	documented in C	27367
@VP	are shown	27764
@VP	shown	27768
@VP	was not different between the groups	27985
@VP	was examined to determine whether cABC had degraded chondroitin sulfate	28317
@VP	examined to determine whether cABC had degraded chondroitin sulfate	28321
@VP	to determine whether cABC had degraded chondroitin sulfate	28330
@VP	determine whether cABC had degraded chondroitin sulfate	28333
@VP	had degraded chondroitin sulfate	28356
@VP	degraded chondroitin sulfate	28360
@VP	recognize either digested or intact chondroitin sulfate	28423
@VP	were used ; an increase of 2B6	28479
@VP	used ; an increase of 2B6	28484
@VP	used	28484
@VP	indicated cABC efficacy	28591
@VP	follows	28665
@VP	followed combined treatment Initially , after the spinal cord transection	28959
@VP	exhibited complete , flaccid paralysis of the hindlimbs	29045
@VP	represented by spontaneous movements of up to two joints of the hindlegs	29118
@VP	was found over the next 5 weeks after injury -LRB- Fig. 3C -RRB-	29192
@VP	found over the next 5 weeks after injury -LRB- Fig. 3C -RRB-	29196
@VP	were not observed before 6 weeks after lesioning	29272
@VP	observed before 6 weeks after lesioning	29281
@VP	lesioning	29311
@VP	manifested by a hunched posture rostral to the laminectomy site	29404
@VP	resulting in asymmetric body posture	29548
@VP	ranging from 0 , no sign of spasticity , to 3 , extensive spasticity	29651
@VP	was found between groups -LRB- data not shown -RRB-	29733
@VP	found between groups -LRB- data not shown -RRB-	29737
@VP	not shown	29764
@VP	impacted locomotor ability	29805
@VP	were standing	30083
@VP	standing	30088
@VP	did not step	30115
@VP	step	30123
@VP	generating networks in the lumbar spinal cord	30194
@VP	excluded from the evaluation of open-field locomotion using the BBB rating scale	30262
@VP	using the BBB rating scale	30316
@VP	pulled out of the channels , but in one animal -LRB- grafts only -RRB-	30389
@VP	spanning ≈ 80 % of the spinal cord	30587
@VP	fulfilled the exclusion criteria	30634
@VP	was removed from the study	30680
@VP	removed from the study	30684
@VP	was performed until 9 weeks postlesion -LRB- Fig. 3A -RRB-	30754
@VP	performed until 9 weeks postlesion -LRB- Fig. 3A -RRB-	30758
@VP	was 4 ± 0.6 -LRB- n = 6 -RRB-	30898
@VP	was 6.6 ± 0.7 -LRB- n = 5 -RRB-	30937
@VP	was significantly higher than that of the other groups -LRB- p < 0.01 -RRB-	30996
@VP	compared with the control group	31160
@VP	was seen until 8 weeks after injury -LRB- Fig. 3C -RRB-	31255
@VP	seen until 8 weeks after injury -LRB- Fig. 3C -RRB-	31259
@VP	ranged between 0 and 4 points	31350
@VP	were observed	31432
@VP	observed	31437
@VP	was discontinued	31665
@VP	discontinued	31669
@VP	is shown in Figure 4	31782
@VP	shown in Figure 4	31785
@VP	is considered in the BBB score only in animals	31971
@VP	considered in the BBB score only in animals	31974
@VP	are able to perform weight-supported plantar stepping	32023
@VP	to perform weight-supported plantar stepping	32032
@VP	perform weight-supported plantar stepping	32035
@VP	stepping	32068
@VP	is also an important outcome measure	32138
@VP	stepping	32243
@VP	is especially needed after complete SCI	32252
@VP	needed after complete SCI	32266
@VP	was analyzed	32358
@VP	analyzed	32362
@VP	was used	32448
@VP	used	32452
@VP	are summarized in Figure 3B	32470
@VP	summarized in Figure 3B	32474
@VP	scored the lowest percentage of forelimb/hindlimb coupling with 18.5 ± 0.5 %	32556
@VP	was evident in the group with grafts and cABC -LRB- 70 ± 3.4 % -RRB-	32731
@VP	was highly significant compared with both the untreated and the grafted groups	32807
@VP	stepping	33060
@VP	descending commands from reestablished motor tracts	33082
@VP	reestablished motor tracts	33107
@VP	examined locomotion on three different surfaces	33138
@VP	was a smooth Plexiglas surface used for all open-field testing	33197
@VP	used for all open-field testing	33228
@VP	covered with a thin layer of oil -LRB- referred to as a slippery surface -RRB-	33296
@VP	referred to as a slippery surface	33330
@VP	to	33339
@VP	was a carpet -LRB- rough surface -RRB-	33380
@VP	sliding over the surface would enhance the hindlimb activity	33541
@VP	would enhance the hindlimb activity	33566
@VP	enhance the hindlimb activity	33572
@VP	increased friction	33622
@VP	were able to increase propulsion	33656
@VP	to increase propulsion	33666
@VP	increase propulsion	33669
@VP	resulted in a nonquantified , but obvious , increase in walking speed	33699
@VP	walking speed	33753
@VP	was either reduced	33805
@VP	was	33805
@VP	reduced	33816
@VP	resulted in stationary walking	33978
@VP	moving the rest of the body relative to the surface	34083
@VP	reducing sensory feedback to the hindlimbs	34151
@VP	was hard to motivate the rats to walk	34222
@VP	to motivate the rats to walk	34231
@VP	motivate the rats to walk	34234
@VP	to walk	34252
@VP	walk	34255
@VP	stepping sequences	34279
@VP	were recorded	34298
@VP	recorded	34303
@VP	was tied to hindlimb activation	34366
@VP	tied to hindlimb activation	34370
@VP	would support the idea that forelimbs and hindlimbs are coupled	34412
@VP	support the idea that forelimbs and hindlimbs are coupled	34418
@VP	are coupled	34464
@VP	coupled	34468
@VP	is involved in triggering locomotion	34506
@VP	involved in triggering locomotion	34509
@VP	triggering locomotion	34521
@VP	alternating forelimb/hindlimb activity	34770
@VP	has occurred	34868
@VP	occurred	34872
@VP	increased response to tactile stimuli	34894
@VP	To test whether the experimental treatments influenced these responses	35118
@VP	test whether the experimental treatments influenced these responses	35121
@VP	influenced these responses	35162
@VP	was the most sensitive and most reliably excitable location	35377
@VP	was consistent between animals	35502
@VP	gathered from stimulation at the base of the tail	35544
@VP	are presented	35594
@VP	presented	35598
@VP	to trigger a response	35654
@VP	trigger a response	35657
@VP	was found in untreated rats -LRB- Fig. 5 -RRB-	35677
@VP	found in untreated rats -LRB- Fig. 5 -RRB-	35681
@VP	was 0.63 ± 0.1 g.	35773
@VP	project serotonergic -LRB- 5-HT-positive -RRB- fibers	36140
@VP	were detected within the graft and caudal to it	36205
@VP	detected within the graft and caudal to it	36210
@VP	was	36275
@VP	caudal to the bridge revealed a high variability within the groups	36411
@VP	revealed a high variability within the groups	36432
@VP	caused by grafting	36517
@VP	grafting	36527
@VP	was not significant -LRB- 70.1 ± 12.2 , SEM in the rats with grafts only -RRB-	36536
@VP	was further enhanced by the application of cABC -LRB- 94 ± 14.5 -RRB-	36619
@VP	further enhanced by the application of cABC -LRB- 94 ± 14.5 -RRB-	36623
@VP	compared with the untreated animals -LRB- 15.5 ± 2.2 -RRB- -LRB- Fig. 6B -RRB-	36718
@VP	was found in our experiment -LRB- Fig. 6C -RRB-	37019
@VP	found in our experiment -LRB- Fig. 6C -RRB-	37023
@VP	tracing of axons of two descending motor tracts -LRB- CST and RtST -RRB-	37069
@VP	was confirmed rostral to the lesion	37132
@VP	confirmed rostral to the lesion	37136
@VP	were able to enter the bridge	37202
@VP	to enter the bridge	37212
@VP	enter the bridge	37215
@VP	observed to enter the caudal part of the spinal cord -LRB- data not shown -RRB-	37247
@VP	to enter the caudal part of the spinal cord -LRB- data not shown -RRB-	37256
@VP	enter the caudal part of the spinal cord -LRB- data not shown -RRB-	37259
@VP	not shown	37306
@VP	was performed in transverse	37420
@VP	performed in transverse	37424
@VP	obtained from the center of the bridge	37462
@VP	both descending and ascending fibers	37530
@VP	can not be distinguished by this approach -LRB- Fig. 7 -RRB-	37572
@VP	be distinguished by this approach -LRB- Fig. 7 -RRB-	37579
@VP	distinguished by this approach -LRB- Fig. 7 -RRB-	37582
@VP	was	37770
@VP	was not statistically different	37792
@VP	compared with the control group -LRB- 3058 ± 600 -RRB- -LRB- Fig. 8A -RRB-	37904
@VP	was found -LRB- Fig. 8C -RRB-	38128
@VP	found -LRB- Fig. 8C -RRB-	38132
@VP	is involved in the observed functional recovery	38204
@VP	involved in the observed functional recovery	38207
@VP	statistically increased when comparing either of the groups -LRB- Fig. 8B -RRB-	38303
@VP	comparing either of the groups -LRB- Fig. 8B -RRB-	38332
@VP	to enhance the viability of the grafted cells within the bridge	38432
@VP	enhance the viability of the grafted cells within the bridge	38435
@VP	to improve support of axonal regeneration	38500
@VP	improve support of axonal regeneration	38503
@VP	grafts only	38627
@VP	were 264 ± 43 -LRB- SEM -RRB- , 357 ± 43 , and 414 ± 50 , respectively	38656
@VP	Testing the interaction of established experimental treatments	38727
@VP	developing additive , more efficacious treatments for SCI	38814
@VP	provides direction for the refinement of future treatments	38906
@VP	compared with untreated rats	38971
@VP	subjected to cell grafts and cABC treatment	39027
@VP	quantified by both the BBB score and forelimb/hindlimb coupling measurements	39139
@VP	are actually much greater than shown for at least two reasons	39543
@VP	shown for at least two reasons	39574
@VP	did not plateau at the end of the allotted testing period	39655
@VP	plateau at the end of the allotted testing period	39663
@VP	determining the long-term benefits of the combinatory treatment	39778
@VP	was not chosen because of small animal numbers in the groups	39846
@VP	chosen because of small animal numbers in the groups	39854
@VP	tracing	39954
@VP	had been completed	39962
@VP	been completed	39966
@VP	completed	39971
@VP	resulted in strong lordosis , further hampering locomotor recovery	40067
@VP	hampering locomotor recovery	40104
@VP	stepping , even if the nervous system had recovered sufficient motor control	40208
@VP	had recovered sufficient motor control	40245
@VP	recovered sufficient motor control	40249
@VP	consisting of SCs and OEG and the application of cABC	40347
@VP	have additive effects	40401
@VP	has shown salutary effects after brain injury	40618
@VP	shown salutary effects after brain injury	40622
@VP	especially suited when applied in conjunction with grafted tissue	40802
@VP	applied in conjunction with grafted tissue	40825
@VP	to grow into and through the graft -LRB- Chau et al. , 2004 -RRB-	40948
@VP	grow into and through the graft -LRB- Chau et al. , 2004 -RRB-	40951
@VP	is noteworthy that one control animal reached a BBB score of 6	41007
@VP	reached a BBB score of 6	41045
@VP	progressed faster than in the treated group	41087
@VP	was unexpected , because the surgery eliminated any chance of axonal sparing	41146
@VP	eliminated any chance of axonal sparing	41182
@VP	could not reduce hindlimb activity	41253
@VP	reduce hindlimb activity	41263
@VP	controlling locomotion	41365
@VP	see Pearson , 2000 ; Edgerton et al. , 2001 ; Rossignol et al. , 2002	41401
@VP	observed in Matrigelonly grafts	41565
@VP	found in Matrigel-only bridges in previous studies -LRB- Xu et al. , 1997 -RRB-	41620
@VP	was the spinal cord pulled out of the channel	41739
@VP	pulled out of the channel	41759
@VP	implanting an SC bridge used in this study	41830
@VP	used in this study	41854
@VP	Inserting the channel first	41874
@VP	may enable better apposition between the SCs and the spinal cord stumps	41995
@VP	enable better apposition between the SCs and the spinal cord stumps	41999
@VP	self-assembles in situ	42195
@VP	is implanted in solid gel form -LRB- Joosten et al. , 1995 -RRB-	42266
@VP	implanted in solid gel form -LRB- Joosten et al. , 1995 -RRB-	42269
@VP	implant is in fluid form	42361
@VP	is in fluid form	42369
@VP	may better conform to the surface of the cord stump	42390
@VP	conform to the surface of the cord stump	42401
@VP	to repair the injured spinal cord	42490
@VP	repair the injured spinal cord	42493
@VP	observed functional recovery	42535
@VP	see Fouad and Pearson , 2004	42724
@VP	have provided evidence of reconnection	42932
@VP	provided evidence of reconnection	42937
@VP	growing through the graft and into the caudal stump of the spinal cord	43061
@VP	were found to enter the SC bridge	43171
@VP	found to enter the SC bridge	43176
@VP	to enter the SC bridge	43182
@VP	enter the SC bridge	43185
@VP	were found to grow through and out of the bridge into the contiguous caudal cord	43215
@VP	found to grow through and out of the bridge into the contiguous caudal cord	43220
@VP	to grow through and out of the bridge into the contiguous caudal cord	43226
@VP	grow through and out of the bridge into the contiguous caudal cord	43229
@VP	grew through the bridge and projected into the caudal stump	43368
@VP	grew through the bridge	43368
@VP	projected into the caudal stump	43396
@VP	were found in abundance	43428
@VP	found in abundance	43433
@VP	led to the presence of 5-HT fibers	43533
@VP	occupying a complete transection gap -LRB- Ramo ' n-Cueto et al. , 1998 -RRB-	43589
@VP	was found	43983
@VP	found	43987
@VP	regenerating serotonergic fibers	44054
@VP	are necessary to promote locomotor recovery	44087
@VP	to promote locomotor recovery	44101
@VP	promote locomotor recovery	44104
@VP	did not grow far enough into the lumbar cord	44137
@VP	grow far enough into the lumbar cord	44145
@VP	were not functional	44197
@VP	were involved in the observed recovery	44416
@VP	involved in the observed recovery	44421
@VP	are known to grow through SC bridges	44522
@VP	known to grow through SC bridges	44526
@VP	to grow through SC bridges	44532
@VP	grow through SC bridges	44535
@VP	were not traced in the present study	44796
@VP	traced in the present study	44805
@VP	should be monitored using retrograde tracers in future work	44837
@VP	be monitored using retrograde tracers in future work	44844
@VP	monitored using retrograde tracers in future work	44847
@VP	using retrograde tracers in future work	44857
@VP	to confirm the relationship between regeneration and functional recovery	44922
@VP	confirm the relationship between regeneration and functional recovery	44925
@VP	would have interfered with the anterograde tracing used in our study	45069
@VP	have interfered with the anterograde tracing used in our study	45075
@VP	interfered with the anterograde tracing used in our study	45080
@VP	tracing used in our study	45112
@VP	used in our study	45120
@VP	supporting a reestablished connection via the lesion site	45149
@VP	reestablished connection via the lesion site	45162
@VP	comes from behavioral testing on a slippery surface	45207
@VP	stepping	45289
@VP	was reduced to a minimum , because no sliding over the surface occurred	45333
@VP	reduced to a minimum , because no sliding over the surface occurred	45337
@VP	occurred	45395
@VP	were activated	45487
@VP	activated	45492
@VP	alternating with the forelimbs	45506
@VP	indicating that both forelimb	45538
@VP	hindlimb stepping	45572
@VP	was triggered by descending input	45590
@VP	triggered by descending input	45594
@VP	does not only involve descending motor axons	45682
@VP	involve descending motor axons	45696
@VP	will also be enhanced	45767
@VP	be enhanced	45777
@VP	enhanced	45780
@VP	did not monitor sprouting of sensory fibers	45809
@VP	monitor sprouting of sensory fibers	45817
@VP	sprouting of sensory fibers	45825
@VP	caudal to the lesion	45919
@VP	treated rats	45958
@VP	impacts the clinical value of regeneration - promoting treatments	46036
@VP	promoting treatments	46080
@VP	would be undesirable	46143
@VP	be undesirable	46149
@VP	do not necessarily have to be interpreted as increased pain or allodynia	46186
@VP	have to be interpreted as increased pain or allodynia	46205
@VP	to be interpreted as increased pain or allodynia	46210
@VP	be interpreted as increased pain or allodynia	46213
@VP	interpreted as increased pain or allodynia	46216
@VP	Paralyzed	46260
@VP	showed signs comparable with spasticity in human patients	46275
@VP	suggested to accentuate locomotor recovery after SCI -LRB- Pearson , 2001 -RRB-	46614
@VP	to accentuate locomotor recovery after SCI -LRB- Pearson , 2001 -RRB-	46624
@VP	accentuate locomotor recovery after SCI -LRB- Pearson , 2001 -RRB-	46627
@VP	reported above	46710
@VP	walking on a rough surface because of greater levels of cutaneous feedback	46772
@VP	was not the case	46862
@VP	texture during a walking sequence initiate reflex-like stepping	46922
@VP	stepping	46977
@VP	stepping stone toward the development of a combined treatment for SCI	47043
@VP	support peripheral nerve regeneration in the absence of a distal nerve stump	48041
